日本臨牀　65/増刊8　医薬品副作用学

出版社： 日本臨牀社
発行日： 2007-10-28
分野： 臨床医学：一般  >  雑誌
雑誌名：
特集： 医薬品副作用学―薬剤の安全使用アップデート―
電子書籍版： 2007-10-28 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

14,300 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

14,300 円(税込)

購入する

目次

  • 日本臨牀　65/増刊8　医薬品副作用学

    ―目次―

    特集　医薬品副作用学―薬剤の安全使用アップデート―

    I． 副作用総論 　 　
    　1　副作用の種類と発生機序
    　2　副作用発生に影響する諸因子
    　3　ゲノム情報に基づいた副作用予測
    　4　医薬品副作用の診断
    　5　使用上の注意
    　6　特殊例への対応 　 　
    　7　副作用・感染症報告制度
    　8　副作用重篤度分類基準
    　9　医薬品副作用被害救済制度

    II． 副作用概論 　 　
    　1　臓器別副作用 　 　
    　2　薬効群別副作用 　 　

    III． 副作用各論−重大な副作用− 　 　
    　1 全身性 　 　
    　2　皮膚 　 　
    　3　精神神経系 　 　
    　4　筋・骨格 　 　
    　5　呼吸器 　 　
    　6　循環器 　 　
    　7　血液 　 　
    　8　消化器 　 　
    　9　肝臓 　 　
    　10　腎臓・泌尿器 　 　
    　11　代謝・内分泌 　 　

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 副作用総論

P.9 掲載の参考文献
1) 松田敏夫 : 薬の副作用. 薬と疾病 I. 薬の効くプロセス (日本薬学会編), p47-50, 東京化学同人, 2004.
 
2) 治験中に得られる安全性情報の取り扱いについて. 平成7年3月20日, 厚生省薬務局審査課長通知, 薬審第227号.
 
3) 医薬品等の副作用の重篤度分類基準について. 平成4年6月29日, 厚生省薬務局安全課長通知, 薬安第80号.
 
4) Lazarou J, et al : Incidence of adverse drug reactions in hospitalized patients : A metaanalysis of prospective studies. JAMA 279 : 1200-1205, 1998.
PubMed
5) Tran C, et al : Gender differences in adverse drug reactions. J Clin Pharmacol 38 : 1003-1009, 1998.
PubMed
6) Beyth RJ, Shorr RI : Epidemiology of adverse drug reactions in the eldery by drug class. Drugs Aging 14 : 231-239, 1999.
 
7) 中村紘一 : 薬物有害反応. 臨床薬理学, 第2版 (日本臨床薬理学会編), p202-206, 医学書院, 2003.
 
8) 麻生芳郎 : 有害薬物反応. 一目でわかる薬理学 薬物療法の基礎知識, 第4版 (麻生芳郎編), p90-91, メディカル・サイエンス・インターナショナル, 2003.
 
9) 島田英世 : 薬物の有害反応. 薬学生のための臨床薬理学, 第3版 (島田英世編), p22-25, 廣川書店, 1997.
 
P.15 掲載の参考文献
1) 日本臨床薬理学会 (編) : 臨床薬理学, 第2版, 医学書院, 2003.
 
2) 加藤隆一 : 臨床薬物動態学, 改訂第3版, 南江堂, 2003.
 
3) 薬物代謝酵素の遺伝的多型-特に個別化薬物治療を目ざして-. 臨床検査 48 (2) : 149-156, 2004
 
P.21 掲載の参考文献
1) Kaniwa N, et al : Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C > T (P229L) found in an African-American. Drug Metab Dispos 33 : 458-465, 2005.
 
2) Saeki M, et al : A combinatorial haplotype of the UDP-glucuronosyltransferase IAI gene (#60-#IB) increases total bilirubin concentrations in Japanese volunteers. Clin Chem 53 : 356-358, 2007.
 
3) Sai K, et al : UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 75 : 501-515, 2004.
PubMed
4) Ando Y, et al : Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity : a pharmacogenetic analysis. Cancer Res 60 : 6921-6926, 2000.
PubMed
5) Minami H, et al : Irinotecan pharmacokinetics/pharmacodynamics and UGTIA genetic polymorphisms in Japanese : Roles of UGT1A1 *6 and *28. Pharmacogenet Genomics 17 : 497-504, 2007.
PubMed
6) Ando M, et al : Genetic polymorphisms of thiopurine S-methyltransferase and 6-mercaptopurine toxicity in Japanese children with acute lymphoblastic leukaemia. Pharmacogenetics 11 : 269-273, 2001.
PubMed
7) Ishioka S, et al : Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med 38 : 944-947, 1999.
PubMed
8) Soejima M, et al : Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res Ther 9 : R23, 2007.
 
9) Tanaka E, et al : Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 29 : 2492-2499, 2002.
 
10) Hiratsuka M, et al : Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab Pharmacokinet 17 : 357-362, 2002.
 
11) Sugiyama E, et al : Pharmacokinetics of gemcitabine in Japanese cancer patients : the impact of a cytidine deaminase polymorphism. J Clin Oncol 25 : 32-42, 2007.
 
12) Yonemori K, et al : Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 11 : 2620-2624, 2005.
 
13) Watanabe I, et al : A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 73 : 435-455, 2003.
PubMed
14) Hung SI, et al : Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 16 : 297-306, 2006.
PubMed
15) Ueta M, et al : Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol 143 : 367 -368, 2007.
 
P.24 掲載の参考文献
1) 高橋隆一 : 医薬品の副作用とその対応. 綜合臨牀 47 : 2605-2606, 1998.
Medical*Online
2) 高橋隆一 : 副作用症例の評価の実際. 医薬品研究 31 : 681-687, 2000.
 
P.33 掲載の参考文献
1) Kearns GL, et al : Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 349 : 1157-1167, 2003.
PubMed
2) 越前宏俊 : 薬物動態と小児の薬物療法. 小児科 47 : 583-588, 2006.
 
3) Kearns GL : Impact of developmental pharmacology on pediatric study design : overcoming the challenges. J Allergy Clin Immunol 106 (3 Suppl) : S128-S138, 2000.
 
4) LacroiX D, et al : Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247 : 625-634, 1997.
PubMed
5) Koukouritaki SB, et al : Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 308 : 965-974, 2004.
PubMed
6) Strassburg CP, et al : Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50 : 259-265, 2002.
PubMed
7) Sonnier M, Cresteil T : Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 251 : 893-899, 1998.
PubMed
8) 志岐甲介ほか : 資料 : 子どもに投与されている医薬品の現状と添付文書の問題点. 日本小児臨床薬理学会誌 17 : 151-158, 2004.
 
9) 木村利美ほか : 添付文書に基づくバンコマイシンの新生児投与について. 日本小児臨床薬理学会誌 14 : 31-34, 2001.
 
10) 砂川慶介, 佐藤吉壮 : 抗菌化学療法薬の適正使用 : 新生児・未熟児への抗菌化学療法薬の使い方. 治療 82 (Suppl) : 558-562, 2000.
 
P.41 掲載の参考文献
1) Lacroix I, et al : Prescription of drugs during pregnancy in France. Lancet 356 : 1735-1736, 2000.
PubMed
2) 佐藤孝道 : 妊婦・授乳婦と薬物療法. 産婦人科治療 86 : 392-395, 2003.
Medical*Online
3) American Academy of Pediatrics Committee on Drugs : Transfer of drugs and other chemicals into human milk. Pediatrics 108 : 776-789, 2001.
 
4) Briggs GG : Drug effects on the fetus and breast-fed infant. Clin Obstet Gynecol 45 : 6-21, 2002.
PubMed
5) Food and Drug Administration : Fed Regist 44 : 37434-37467, 1980.
 
P.47 掲載の参考文献
1) 荻原俊男, 三上洋 : 老年病の特徴と薬物療法. 老化と疾患 7 : 1505-1510, 1994.
 
2) Sorock GS, Shimkin EE : Benzodiazepine sedatives and the risk of falling in a community-dwelling elderly cohort. Arch Intern Med 148 : 2441-2444, 1988.
 
3) Tsujimoto G, et al : Pharmacokinetic and pharmacodynamic principles of drug therapy in old age. Part 1. Int J Clin Pharmacol Ther Toxicol 27 : 13-26, 1989.
PubMed
4) Lamy PP : The elderly and drug interactions. J Am Geriatr Soc 34 : 586-593, 1986.
PubMed
5) 上島悦子ほか : 老年患者の服薬コンプライアンス. 日老医誌 29 : 855-863, 1992.
 
6) Hanlon JT, et al : Use of inappropriate prescription drugs by older people. J Am Geriatr Soc 50 : 26-34, 2002.
 
7) Gurwitz JH, et al : Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289 : 1107-1116, 2003.
PubMed
8) Montamat SC, et al : Management of drug therapy in the elderly. N Engl J Med 321 : 303-309, 1989.
PubMed
P.52 掲載の参考文献
1) Sullivan TJ : Drug allergy. In : Allergy-Principles and Practice-, p 1726-1746, Mosby, St. Louis, 1993.
 
2) Ansel G, et al : The current status of reactions to intravenous contrast media. Invest Radiol 15 : S32-39, 1980.
 
3) Katayama H, et al : Adverse reactions to ionic and nonionic contrast media. Radiol ogy 175 : 621-628, 1990.
 
4) Greenberger PA, Patterson R : The prevention of immediate generalized reactions to radiocontrast mediain high-risk patients. J Allergy Clin Immunol 87 : 867-872, 1991.
 
5) Fischer HW, Doust VL : An evaluation of pretesting in the problem of serious and fatal reactions to excretory urography. Radiol ogy 103 : 497-501, 1972.
 
6) Witten DM : Reactions to urographic contrast media. JAMA 231 : 974-977, 1975.
PubMed
7) Tramer MR, et al : Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media : systematic review. BMJ 333 : 675-678, 2006.
PubMed
8) Morcos SK, et al : Prevention of generalized reactions to contrast media : a contrast media : a consensus report and guidelines. Eur Radiol 11 : 1720-1728, 2001.
PubMed
9) Witte RJ, Anzai LL : Life-threatening anaphylactoid reaction after intravenous gadoteridol administration in a patient who had previously received gadopentetate dimeglumine. AJNR Am J Neuroradiol 15 : 523-524, 1994.
 
10) Kevin LN, et al : Clinical safety of gadopentetate dimeglumine. Radiol ogy 196 : 439-443, 1995.
 
11) Szczeklik A, et al : Hydrocortisone and airflow impairment in aspirin-induced asthma. J Allergy Clin Immunol 76 : 530-536, 1985.
PubMed
12) Settipane GA : Aspirin and allergic disease : a review. Am J Med 74 : 102-109, 1983.
PubMed
13) Szczeklik A, Sanak M : The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors. Clin Exp Allergy 32 : 339-342, 2002.
PubMed
14) Toogood JH : Risk of anaphyla) ds in patients receiving beta-blocker drugs. J Allergy Clin Immunol 81 : 1, 1988.
 
15) 吉田雄一 : 抗生剤の経静脈投与による副反応の分析. 臨床と薬物治療 20 : 654-657, 2001.
 
16) Pilipchuk VN : The side effects of antibiotics in chronic bronchitis. Vrach Delo 6 : 38-40, 1990.
PubMed
P.57 掲載の参考文献
1) 越前宏俊 : 薬物動態理論. 内科学 (金澤一郎ほか編), p261-267, 医学書院, 2006.
 
2) 佐川通夫ほか : 痩せ薬・健康食品による薬物性肝障害2次全国調査集計結果 (日本肝臓学会主催). 肝臓 45 : 96-107, 2004.
 
3) Pugh RN : Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 : 646-649, 1973.
PubMed
4) 小池勇一 : 病態時における薬物動態と薬物投与計画. 臨床薬物治療学大系 (海老原昭夫ほか編), p239, 情報開発研究所, 1988.
 
5) 大西明弘 : 肝疾患患者の薬物療法. 臨床薬理 36 : 221-225, 2005.
 
6) 越前宏俊 : 肝障害時における薬物投与計画. 臨床薬理学 (中野重行ほか編), p299-312, 医学書院, 2003.
 
7) Hasegawa M, et al : Fasting plasma caffeine level in cirrhotic patients : relation to plasma levels of catecholamines and renin activity. Hepatology 10 : 973-977, 1989.
PubMed
8) Yamada S, et al : Clinical significance of benzoate-metabolizing capacity in patients with chronic liver disease : pharmacokinetic analysis. Res Commun Chem Pathol Pharmacol 76 : 53-62, 1992.
PubMed
9) 川崎寛中, 村脇義和 : 肝臓病-専門医に聞く最新の臨床 (戸田剛太郎ほか編), p204-205, 中外医学社, 2003.
 
10) 周防武昭, 山田貞子 : 肝疾患患者に対する薬物投与. 医学のあゆみ 214 : 907-911, 2005.
Medical*Online
11) 鳥取大学医学部附属病院医薬品集, 16版, 2006.
 
12) 周防武昭, 山田貞子 : 肝機能障害患者に投薬を行うときの注意点は? JOHNS 23 : 341-342, 2007.
Medical*Online
13) Areberg J, et al : The pharmacokinetics of escitalopram in patients with hepatic impairment. AAPS J 8 : E14-19, 2006.
PubMed
14) 滝川一・ほか : DDW-J 2004ワークショップ 薬物性肝障害診断基準の提案. 肝臓 46 : 85-90, 2005.
 
15) Kuipers M, et al : Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment. J Pharmacol Sci 102 : 405-412, 2006.
PubMed
P.66 掲載の参考文献
1) 長谷川功ほか : 腎機能障害患者に投薬や輸液を行うときの注意点は? JOHNS 23 (3), 2007.
Medical*Online
2) 木村健二郎 : 付録B腎障害をおこす薬物の機序と治療上の代替薬. WM腎臓内科コンサルト, p 340, メディカル・サイエンス・インターナショナル, 2006.
 
3) 平田純生 : 腎不全と薬の使い方Q&A-腎不全時の薬物投与一覧, じほう, 2005.
 
4) Aronoff G : Drug Prescribing in Renal Failure : Dosing Guidelines for Adults, American College of Physicians, Philadelphia, 2007.
 
5) Lacy CF : Lexi-Comp's Drug lnformation Handbook International : With Canadian and International Drug Monographs, Lexi Comp, Ohio, 2006.
 
6) 乾賢一ほか : 改訂2版腎機能別薬剤使用マニュアル, じほう, 2006.
 
7) 木村健二郎 : 付録C薬物相互作用. WM腎臓内科コンサルト, p 341, メディカル・サイエンス・インターナショナル, 2006.
 
8) http://www.uptodate.com/
 
9) 神谷大雄 : 薬の相互作用としくみ (杉山正康編), 医歯薬出版, 2005.
 
10) Gabardi S, Abramson S : Drug dosing in chronic kidney disease. Med Clin North Am 89 : 649-687, 2005.
PubMed
11) http://medicine.iupui.edu/flockhart/clinlist.htm
 
12) Leblond FA, et al : Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol 13 : 1579-1585, 2002.
PubMed
13) Veau C, et al : Efifect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion. Nephrol Dial Transplant 16 : 1607-1614, 2001.
 
14) Tett SE, et al : Principles and clinical application of assessing alterations in renal elimination pathways. Clin Pharmacokinet 42 : 1193-1211, 2003.
PubMed
15) http://www.nephrologypharmacy.com/
 
P.72 掲載の参考文献
1) 医薬品・医療機器等安全性情報 医療機関報告のお願い : http://www.info. pmda.go.jp/info/houkoku. html
 
2) 医薬品製造販売指針2006, じほう, 2006.
 
P.80 掲載の参考文献
1) 藤井俊志 : 12医薬品情報業務の実際. 医薬品情報学 (小清水敏昌編著), p158-172, 朝倉書店, 1998.
 
2) 高橋春男 : 3章市販後調査と情報. 医薬品情報学第3版 (山崎幹夫監), p24-36, 東京大学出版会, 2005.
 
3) 医薬品等の副作用の重篤度分類基準について, 薬安第80号 (厚生省薬務局安全課課長通知), 1992.
 
4) National Cancer Institute-Common Toxicity Criteria (NCI-CTC Version 2. 0, April 30, 1999) ～日本語訳JCOG版-第2版～ (日本臨床腫瘍研究グループ), 初版1999年4月, 第1回改訂2001年9月.
 
5) 有害事象共通用語規準v3.0日本語訳JCOG/JSCO版-2004年10月27日 Common Terminology Criteria for Adverse Events v3.0 (CTCAE) -December 12, 2003. (http://www.jcog.jp/SHIRYOU/fra_ma_guidetop.htm)
 
P.86 掲載の参考文献
1) http://www.pmda.go.jp/kenkouhigai/help.html
 
2) http://www.pmda.go.jp/kenkouhigai/help/request.html
 
3) http://www.pmda.go.jp/kenkouhigai/help/taisyou.html
 

II 副作用概論

P.93 掲載の参考文献
1) Kaplowitz N : Drug-induced liver disorders : introduction and overview. In : Drug-induced Liver Disease, 1st ed (ed by Kaplowitz N, DeLeve LD), p 1-13, Marcel Dekker, New York, 2003.
 
2) Kumashiro R, et al : Association of troglitazone-induced liver injury with mutation of the cytochrome P450 2C19 gene. Hepatol Res 26 : 337-342, 2003.
PubMed
3) Watanabe I, et al : A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Phamlacol Ther 73 : 435-455, 2003.
PubMed
4) 為田靱彦ほか : 薬剤性肝障害の全国集計. 最新肝臓病学 (渡辺明治, 樋口清博編), p50-61, 新興医学社, 東京, 2001.
 
5) Iwasa M, et al : Modified diagnostic criteria of drug-induced liver injury proposed by the international consensus meeting. Hepatogastroenterology 52 : 869-874, 2005.
PubMed
6) 滝川一ほか : DDW-J 2004ワークショップ薬物性肝障害診断基準の提案. 肝臓 46 : 85-90, 2005.
 
P.98 掲載の参考文献
1) 厚生省医薬安全対策研究会 : 症状別副作用報告の概要. 医薬品副作用要覧「第2集」, p 1245-1251, ミクス, 1998.
 
2) 酒井紀 : 「老人の薬物性腎障害」分科会調査研究報告書. 厚生省特定疾患進行性腎障害調査研究班平成7年度業績, p63-67, 1996.
 
3) 大園恵幸ほか : 尿路性器系疾患 薬剤性腎障害. 日本臨牀 60 (増刊号1) : 493-500, 2002.
 
4) 菱田明 : 薬剤性腎障害の種類. 医学のあゆみ 215 : 501-505, 2005.
 
5) 大野岩男 : [薬剤性腎障害] NSAIDsによる腎障害. Nephrology Frontier 3 : 97-101, 2004.
 
6) 両角國男, 武田朝美 : 免疫抑制剤による薬物性腎障害. 医学のあゆみ 215 : 533-539, 2005.
 
7) Hall CL, et al : The natural course of gold nephropathy : long term study of 21 patients. Br Med J 295 : 745-748, 1987.
 
8) Finkelstein A, et al : Fenoprofen nephropathy : lipoid nephrosis and interstitial nephritis. A possible T-lymphocyte disorder. Am J Med 72 : 81-87, 1982.
PubMed
9) Alper AB Jr, et al : Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am J Kidney Dis 40 : 1086-1090, 2002.
PubMed
10) Fung MC, et al : A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 85 : 2023-2032, 1999.
PubMed
11) Toto RD : Acute tubulointerstitial nephritis. Am J Med Sci 299 : 392-410, 1990.
PubMed
P.104 掲載の参考文献
1) Young NS, Maciejewski J : The pathophysiology of acquired aplastic anemia. N Engl J Med 336 : 1365-1372, 1997.
PubMed
2) Baumelou E, et al : Epidemiology of aplastic anemia in France : a case-control study. I. Medical history and medication use. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood 81 : 1471-1478, 1993.
 
3) Guinan EL, Shimamura A : Acquired and inherited aplastic anemia syndromes. In : Wintrobe's Clinical Hematology (ed by Greer Jp, et al), 11th ed, p 1397-1419, Lea & Febiger, Philadelphia/London, 2003.
 
4) Bacigalupo A ; Working Party on Severe Aplastic Anaemia of the European Blood and Marrow Transplantation Group : Aetiology of severe aplastic anaemia and outcome after allogeneic bone marrow transplantation or immunosuppression therapy. Eur J Haematol Suppl 60 : 16-19, 1996.
PubMed
5) Habibi B : Drug induced red blood cell autoantibodies co-developed with drug specific antibodies causing haemolytic anaemias. Br J Haematol 61 : 139-143, 1985.
PubMed
6) Thomas AT : Autoimmune hemolytic anemias. In : Wintrobe's Clinical Hematology (ed by Lee G, et al), 10th ed, p 1233-1263, Lea & Febiger, Philadelphia/London, 1998.
 
7) Neff AT : Autoimmune hemolytic anemia. In : Wintrobe's Clinical Hematology (ed by Greer JP, et al), 11th ed, p 1157-1182, Lea & Febiger, Philadelphia/London, 2003.
 
8) Watt RG : Neutropenia. In : Wintrobe's Clinical Hematology (ed by Greer JP, et al), 11th ed, p 1777-1800, Lea & Febiger, Philadelphia/London, 2003.
 
9) Young NS : Agranulocytosis. JAMA 271 : 935-938, 1994.
PubMed
10) Andersohn F, et al : Systematic review : Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 146 : 657-665, 2007.
PubMed
11) Deitcher SR, Rodgers GH : Thrombosis and antithrombotic therapy. In : Wintrobe's Clinical Hematology (ed by Greer JP, et al), 11th ed, p 1714-1758, Lea & Febiger, Philadelphia/London, 2003.
 
12) Levine SP : Thrombocytopenia caused by immunologic platelet destruction. In : Wintrobe's Clinical Hematology (ed by Greer JP, et al), 11th ed, p 1534-1554, Lea & Febiger, Philadelphia/London, 2003.
 
13) George JN, et al : Drug-induced thrombocytopenia : a systematic review of published case reports. Ann Intern Med 129 : 886-890, 1998.
PubMed
P.111 掲載の参考文献
1) 伊崎誠一 : 統計から見た最近の薬疹の傾向 : 埼玉県における薬物副作用調査 (1995-2002) の集計から. 日本皮膚アレルギー学会雑誌 12 : 45-51, 2004.
 
2) 塩原哲夫ほか (編) : 薬疹を極める, p1-299, 文光堂, 2006.
 
P.117 掲載の参考文献
1) Frishman WH, et al : Cardiovascular toxicity with cancer chemotherapy. Curr Probl Cardiol 21 : 225-288, 1996.
PubMed
2) Shan K, et al : Anthracycline-induced cardiomyopathy. Ann Intern Med 125 : 47-58, 1996.
PubMed
3) Olson RD, Mushlin PS : Doxorubicin cardiotoXicity : Analysis of prevailing hypotheses. FASEB J 4 : 3076-3086, 1990.
PubMed
4) Mimnaugh EG, et al : Enhancement of reactive oxygen-dependent mitochondrial membrane lipid peroxidation by the anticancer drug adriamycin. Biochem Pharmacol 34 : 847-856, 1985.
PubMed
5) Muindi JR, et al : Hydroxyl radial production and DNA damage induced by anthracycline-iron complex. FEBS Lett 172 : 226-230, 1984.
 
6) Antibiotics : Doxorubicin HCI. In : Drug Facts and Comparisons (ed by Cada DJ), 48th ed, p 2705, Facts and Comparisons, St. Louis, 1994.
 
7) Speyer JL, Freedberg R : Toxicities of therapy : Cardiac complications. In : Clinical Oncology (ed by Abeloff MD, et al), p 809-819, Churchill Livingstone, New York, 1995.
 
8) Von Hoff DD, et al : Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91 : 710-717, 1979.
PubMed
9) Leandro J, et al : Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol 74 : 1152-1156, 1994.
PubMed
10) Steinherz LJ, et al : Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266 : 1672-1677, 1991.
PubMed
11) Stoddard MF, et al : Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 20 : 62-69, 1992.
PubMed
12) Bristow MR, et al : Doxorubicin cardiomyopathy : Evaluation of phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88 : 168-175, 1978.
PubMed
13) Schwartz RG, et al : Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy : Seven-year experience using radionuclide angiocardiography. Am J Med 82 : 1109-1118, 1978.
 
14) Torti FM, et al : Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 99 : 745-749, 1983.
PubMed
15) Legha SS, et al : Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 89 : 133-139, 1982.
 
16) DuBois JS, et al : Severe reversible, global and regional ventricular dysfunction associated with high-dose interleukin-2 immunotherapy. J Immunother 18 : 119-123, 1995.
 
17) Vial T, Descotes J : Clinical toxicity of the interferons. Drug Saf 10 : 115-150, 1994.
PubMed
18) Roose SP, Dalak GW : Treating the depressed patients with cardiovascular problems. J Clin Psychiatry 53 : 25-31, 1992.
 
19) Cole JO, Bodkin JA : Antidepressant drug side effects. J Clin Psychiatry 51 : 21-26, 1990.
PubMed
20) Pimentel L, Trummer L : Cyclic antidepressant overdose : a review. Emerg Med Clin North Am 12 : 533-547, 1994.
 
21) Jefferson JW : Cardiovascular effects and toxicity of anxiolytics and antidepressants. J Clin Psychiatry 50 : 368-378, 1989.
PubMed
22) Goldman LS, et al : Monoamine oxidase inhibitors and tricyclic antidepressants : Comparison of their cardiovascular effects. J Clin Psychiatry 148 : 512-516, 1991.
 
23) Guttmacher LB, Goldstein MG : Treatment of the cardiac-impaired depressed patient. Part 2 : Lithium, carbamazine, and electroconvulsive therapy. Psychiatr Med 6 : 34-51, 1988.
 
24) MacMahon B, et al : Cardiac arrhythmias after intravenous cimetidine. N Engl J Med 305 : 832-833, 1981.
PubMed
25) Haverkamp W, et al : Torsades de pointes. In : Cardiac Electrophysiology : From Cell to Bedside (ed by Zipes DP, Jalife J), 2nd ed, p 885-899, Saunders, Philadelphia, 1995.
 
P.124 掲載の参考文献
1) 日本呼吸器学会薬剤性肺障害ガイドライン作成委員会 (編) : 薬剤性肺障害の評価, 治療についてのガイドライン, メディカルレビュー社, 2006.
 
2) American Thoracic Society ; European Respiratory Society : American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the ldiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165 : 277 -304, 2002.
 
3) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会 (編) : 特発性間質性肺炎の診断と治療の手引き, 南江堂, 2004.
 
4) 妹川史朗ほか : 薬剤誘起性好酸球性肺炎. 日本胸部臨床 62 : 1000-1005, 2003.
Medical*Online
5) 安井正英, 藤村正樹 : 診断 : DLSTとチャレンジテストの意義. 薬剤による呼吸器障害 (吉澤靖之編), p16-23, 克誠堂出版, 2005.
 
P.130 掲載の参考文献
1) 塩川優一ほか : 非ステロイド性抗炎症剤による上部消化管傷害に関する疫学調査. リウマチ 31 : 96, 1991.
 
2) Hawkey CJ, et al : Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs : HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 352 : 1016-1021, 1998.
PubMed
3) Conn HO, Blitzer BL : Nonassociation of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 294 : 473-479, 1976.
PubMed
4) Piper JM, et al : Corticosteroid use and peptic ulcer disease : role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 114 : 735-740, 1991.
PubMed
P.136 掲載の参考文献
1) Sadock BJ, Sadock VA : Kaplan & Sadock'sSynopsis of Psychiatry, 9th ed, p 534-590, Lippincott Williams & Wilkins, Philadelphia, 2003.
 
2) Ko DT, et al : Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMLA. 288 : 351-357, 2002.
 
3) Lewis DA, Smith RE : Steroid-induced psychiatric syndromes ; A report of 14-cases and a review of the literature. J Affect Disord 5 : 319-332, 1983.
 
4) 高木洲一郎 : インターフェロン療法中の精神症状. 精神医学 37 : 344 -358, 1995.
 
5) 高木洲一郎ほか : インターフェロン療法中の精神療法. 日医新報 3732 : 29-34, 1995.
 
6) 秋山一文 : 医薬品による精神障害. 臨床精神医学講座10 (松下正明編), p487-510, 中山書店, 1997.
 
7) 渡邊崇, 下田和孝 : 薬物有害反応. 臨床精神神経薬理学テキスト (染矢俊幸編), p99-109, 星和書店, 2006.
 
8) Pisani F, et al : Effects of psychotropic drugs on seizure threshold. Drug Saf 25 : 91-110, 2002.
PubMed
9) Peck AW, et al : Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry 44 : 197-201, 1983.
PubMed
10) 西嶋康一 : 副作用とその対策- (3) 悪性症候群-. 精神科治療学 15 (増刊) : 187-191, 2000.
 
P.142 掲載の参考文献
1) Romeo JH, et al : Hyperprolactinaemia and verapamil : prevalence and potential association with hypogonadism in men. Clin Endocrinol (Oxf) 45 (5) : 571-575, 1996.
PubMed
2) Basaria S, Cooper DS : Amiodarone and the thyroid. Am J Med 118 (7) : 706-714, 2005.
PubMed
3) Mandac JC, et al : The clinical and physiological spectrum of interferon-alpha induced thyroiditis : toward a new classification. Hepatology 43 (4) : 661-672, 2006.
 
4) Izzedine H : Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45 (5) : 804-817, 2005.
PubMed
5) Adrogue HJ, Madias NE : Primary care : Hyponatremia. N Engl J Med 342 : 1581-1589, 2000.
 
6) Hammond IW, et al : Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine : an over-representation of Asians? Pharmacoepidemiol Drug Saf 11 (3) : 229-234, 2002.
PubMed
7) Zhang H, et al : Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 102 (26) : 9406-9411, 2005.
PubMed
8) Guan Y, et al : Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11 (8) : 861-866, 2005.
PubMed
9) Chou CL, et al : Acquired bartter-like syndrome associated with gentamicin administration. Am J Med Sci 329 (3) : 144-149, 2005.
PubMed
10) Tveskov C, et al : Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta 2-adrenergic stimulation with terbutaline in healthy subjects. Chest 106 (6) : 1654-1659, 1994.
PubMed
11) Juurlink DN, et al : Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (6) : 543-551, 2004.
PubMed
12) Caliskan Y, et al : Cyclosporine-associated hyperkalemia : report of four allogeneic blood stem-cell transplant cases. Transplantation 75 (7) : 1069-1072, 2003.
PubMed
13) Higgins R, et al : Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities. Nephrotoxicities. Nephrol Dial Transplant 19 (2) : 444-450, 2004.
 
14) Muto S, et al : Effect of nafamostat mesilate on Na+ and K+ transport properties in the rabbit cortical collecting duct. Br J pharmacol 109 (3) : 673-678, 1993.
 
15) Muto S, et al : Effect of trimethoprim-sulfamethoxazole on Na and K+ transport properties in the rabbit cortical collecting duct perfused in vitro. Nephron Physiol 102 (3-4) : 51-60, 2006.
 
16) Hayashi M, et al : Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis : a randomized prospective multicentre trial. Nephrol Dial Transplant 19 (8) : 2067-2073, 2004.
 
17) Ohigashi S, et al : Topical treatment with 22-oxacalcitriol (OCT), a new vitamin D analogue, caused severe hypercalcemia with exacerbation of chronic renal failure in a psoriatic patient with diabetic nephropathy ; a case report and analysis of the potential for hypercalcemia. Intern Med 42 (12) : 1202-1205, 2003.
 
P.145 掲載の参考文献
1) Multidisciplinary Medication Management Project. Top ten dangerous drug interactions in long-term care. http://www.scoup.net/M3Project/topten/
 
2) Cannegieter SC, et al : Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333 : 11-17, 1995.
PubMed
3) Singer DE, et al : Antithrombotic therapy in atrial fibrillation : The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 : 429S-456S, 2004.
PubMed
4) Mathiesen T, et al : Intracranial traumatic and non-traumatic haemorrhagic complications of warfarin treatment. Acta Neurol Scand 91 : 208-214, 1995.
PubMed
5) Shorr RI, et al : Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 153 : 1665-1670, 1993.
PubMed
6) Wolfe MM, et al : Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 : 1888-1899, 1999.
PubMed
7) Byrd DC, et al : Warfarin and cipronoxacin interaction : case report and controversy. J Am Board Fam Pract 12 : 486-488, 1999.
PubMed
8) Ellis RJ, et al : Ciprofloxacin-warfarin coagulopathy : a case series. Am J Hematol 63 : 28-31, 2000.
PubMed
9) Levine M, Sheppard I : Biphasic interaction of phenytoin with warfarin. Clin Pharm 3 : 200-203, 1984.
PubMed
10) Gaeta TJ, et al : Potential drug-drug interactions in elderly patients presenting with syncope. J Emerg Med 22 : 159-162, 2002.
PubMed
P.151 掲載の参考文献
1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators : Preliminary report : effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321 : 406-412, 1989.
 
2) 佐藤信範ほか : 薬剤相互作用におけるQT延長リスクの検討. 厚生労働省科学研究費補助金 (医薬品等医療技術リスク評価研究事業). 平成14年度, 15年度分担研究報告書, p6-18, 2003, p7-15, 2004.
 
3) 清水渉 : 薬物と心電図異常. 新,目でみる循環器病シリーズ「心電図」 (村川裕二編), p 84-95, メジカルビュー社, 2005.
 
4) 藤中祐美子ほか : 心房細動におけるwarfarin療法の現状. Ther Res 23 : 895-897, 2002.
Medical*Online
5) 循環器病の診断と治療に関するガイドライン (1999-2000年度合同研究班報告) 心房細動治療 (薬物) ガイドライン. Jpn Circ J 65 : 931-979, 2001.
 
6). 高橋晴美 : CYP2C9多型とワルファリン応答性の個人差. 心電図 26 : 211-216, 2006.
Medical*Online
7) Serebruany VL, et al : Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 95 : 1218-1222, 2005.
PubMed
8) Takikawa H : Lessons from ticlopidine-induced liver injury. Hepatol Res 33 : 193-194, 2005.
PubMed
9) Brophy JM, et al : A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. Am Heart J 152 : 263-269, 2006.
PubMed
10) 高橋京子, 東純一 : 薬物相互作用と副作用. 臨床医薬 22 : 557-569, 2006.
Medical*Online
11) Keeling D, et al ; Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology : The management of heparin-induced thrombocytopenia. Br J Haematol 133 : 259-269, 2006.
PubMed
12) Warkentin TE, Greinacher A : Heparin-induced thrombocytopenia : recognition, treatment, and prevention : the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 : 311S-337S, 2004.
PubMed
13) 日本脳卒中学会医療向上・社会保険委員会rt-PA (アルテプラーゼ) 静注療法指針部会 : rt-PA (アルテプラーゼ) 静注療法適正治療指針 2005年10月 (解説). 脳卒中 27 : 327-354, 2005.
 
14) Sakaeda T : MDR1 genotype-related pharmacokinetics : fact or fiction? Drug Metab Pharmacokinet 20 : 391-414, 2005.
 
15) Rathore SS, et al : Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 : 871-878, 2003.
PubMed
P.157 掲載の参考文献
1) Furberg CD, et al : Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 92 : 1326-1331, 1995.
PubMed
2) The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 319 : 385 -392, 1988.
 
3) Schweizer MW, et al : Heart rate variability in time and frequency domains : Effects of gallopamil, nifedipine, and metoprolol compared with placebo. Br Heart J 70 : 252-258, 1993.
PubMed
4) Kouvaras G, et al : Effect of nifedipine on the sick sinus syndrome. Angiology 40 : 450-457, 1989.
PubMed
5) Hamada T, et al : Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. J Hypertens 16 : 111-118, 1998.
PubMed
6) Grossman E, et al : Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 276 : 1328-1331, 1996.
PubMed
7) Bailey DG, et al : Grapefruit juice-drug interactions. Br J Clin Pharmacol 46 : 101-110, 1998.
PubMed
8) Baker JG : The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol 144 : 317-322, 2005.
 
9) Rutan GH, et al ; CHS Collaborative Research Group : Orthostatic hypotension in older adults. The Cardiovascular Health Study. Hypertension 19 : 508-519, 1992.
 
10) Cleophas TJ, et al ; Nebivolol Follow-Up Study Group : Paradoxical pressor effects of β-blockers in standing elderly patients with mild hypertension : a beneficial side effect. Circulation 105 : 1669-1671, 2002.
 
11) Yasue H, et al : Prinzmetar s variant form of angina as a manifestation of alpha-adrenergic receptor-mediated coronary artery spasm : documentation by coronary arteriography. Am Heart J 91 : 148-155, 1976.
PubMed
12) Drakos SG, et al : Exacerbation of variant angina by metoprolol resulting in syncope due to transient atrioventricular block. Int J Cardiol 82 : 83-85, 2002.
PubMed
13) Lilja JJ, et al : Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther 73 : 192-198, 2003.
PubMed
14) Lilja JJ, et al : Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol. Clin Pharmacol Ther 75 : 184-190, 2004.
PubMed
15) 長谷川純一 : カルシウム拮抗薬・β遮断薬. 臨牀と研究 83 : 1115-1120, 2006.
Medical*Online
P.162 掲載の参考文献
1) Stumpe KO, et al : Captopril and enalapril : Evaluation of therapeutic efficacy and safety. Pract Cardiol 10 : 111-124, 1984.
 
2) Rush JE, et al : The safety and tolerability of lisinopril in clinical trials. J Cardiovasc Pharmacol 9 (Suppl 3) : S99-107, 1987.
 
3) Cooper WD, et al : Post-marketing surveillance of enalapril : experience in 11,710 hypertensive Patlents in general practice. J R Coll Gen Pract 37 : 346-349, 1987.
 
4) Chalmers D, et al : Post marketing surveillance of captopril (for hypertension) : a preliminary report. Br J Clin Pharmacol 24 : 343-349, 1987.
PubMed
5) Inman WH, et al : Postmarketing surveillance of enalapril. I : Results of prescription-event momtoring. Br Med J 297 : 826-829, 1988.
 
6) Frank GJ, et al : Overall tolerance and safety of quinapril in clinical trials. Angiology 40 : 405-415, 1989.
PubMed
7) Schoenberger JA, et al : Efficacy, safety, and quality of life assessment of captopril antihypertensive therapy in clinical practice. Arch Intern Med 150 : 301-306, 1990.
PubMed
8) Chalmers D, et al : Postmarketing surveillance of captopril for hypertension. Br J Clin Pharmacol 34 : 215-223, 1992.
PubMed
9) Fallovvfield JM, et al : Post-marketing surveillance of lisinopril in general practice in the UK. Br J Clin Pract 47 : 296-304, 1993.
 
10) Huckell VF, et al : Lisinopril in the treatment of hypertension : a Canadian postmarketing surveillance study. Clin Ther 15 : 407 -422, 1993.
 
11) Larochelle P, et al : A postmarketing surveillance evaluation of quinapril in 3742 Canadian hypertensive patients : the ACCEPT Study. Accupril Canadian Clinical Evaluation and Patient Teaching. Clin Ther 16 : 838-853, 1994.
 
12) 関顕 : ACE阻害薬治療上の副作用とその対策. ACEのすべて, 第3版, P310-324, 先端医学社, 1999.
 
13) Jett G K : Captopril-induced angioedema. Ann Emerg Med 13 : 489-490, 1984.
PubMed
14) Suarez M, et al : Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy. Am J Med 81 : 336-338, 1986.
PubMed
15) Giannoccaro pJ, et al : Fatal angioedema associated with enalapril. Can J Cardiol 5 : 335-336, 1989.
PubMed
16) Jason DR, et al : Fatal angioedema associated with captopril. J Forensic Sci 37 : 1418-1421, 1992.
PubMed
17) Ulmer JL, Garvey MJ : Fatal angioedema associated with lisinopril. Ann Pharmacother 26 : 1245-1246, 1992.
PubMed
18) Oike Y, et al : Fatal angioedema associated with enalapril. Intern Med 32 : 308-310, 1993.
PubMed
19) Israili ZH, Hall WD : Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 117 : 234-242, 1992.
PubMed
20) Slater EE, et al : Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 260 : 967-970, 1988.
PubMed
21) Brown NJ, et al : Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 60 : 8-13, 1996.
PubMed
22) Pillans PI, et al : Angiooedema and urticaria with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol 51 : 123-126, 1996.
PubMed
23) Shionoiri H, et al : A case report of angioedema during long-term (66 months) angiotensin converting enzyme inhibition therapy with enalapril. Jpn Cric J 60 : 166-170, 1996.
 
24) Matsumura M, et al : Angioedema likely related to angiotensin converting enzyme inhibitors. Intern Med 32 : 424-426, 1993.
PubMed
25) 丹羽真理子ほか : Enaraprilによる血管神経性浮腫によって上気道閉塞を生じた1例. 内科 73 : 954-957, 1994.
 
26) 神木茂樹ほか : アンジオテンシン変換酵素阻害薬により誘発された舌, 口底部血管神経性浮腫の1例. 日口外会誌 42 : 726-728, 1996.
 
27) 加藤理加ほか : ACE阻害剤服用中に血管性浮腫を生じた2症例. 日耳鼻 99 : 1492-1493, 1996.
 
28) Town GI, et al : Angiotensin converting enzyme inhibitors and cough. N Z Med J 100 : 161-163, 1987.
PubMed
29) Inman WH : Enalapril-induced cough. Lancet ii : 1218, 1986.
 
30) Simon SR, et al : Cough and ACE inhibitors. Arch Intern Med 152 : 1698-1700, 1992.
PubMed
31) 広田憲威ほか : 重回帰分析法によるenalapril誘発咳順の患者背景因子に関する研究. 臨床薬理 26 : 737-742, 1995.
 
32) Sebastian JL, et al : Angiotensin-converting enzyme inhibitors and cough. Prevalence in an outpatient medical clinic population. Chest 99 : 36-39, 1991.
 
33) Poole MD, Postma DS : Characterization of cough associated with angiotensin-converting enzyme inhibitors. Otolaryngol Head Neck Surg 105 : 714-716, 1991.
PubMed
34) Yeo W, et al : Prevalence of persistent cough during long-term enalapril treatment : controlled study versus nifedipine. Q J Med 80 : 763 -770, 1991.
 
35) Erslev AJ, et al : Hematologic side effects of captopril and associated risk factors. Cardiovasc Rev Rep 3 : 660-671, 1982.
 
36) Matsumura M, et al : Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients. Risks of Cardiac Disease in Dialysis Patients Study Group. Nephron 77 : 164-168, 1997.
 
37) Goldberg A, Sweet C : Efficacy and safety of losartan. Can J Cardiol 11 (Suppl F) : 27F-32F, 1995.
 
38) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Mitihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial : Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care : The Aritihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial (ALLHAT-LLT). JAMA 288 : 2998-3007, 2002.
 
39) Kostis JB, et al ; SHEP Collaborative Research Group : Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95 : 29-35, 2005.
 
40) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Arltihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 : 2981-2997, 2002.
PubMed
41) Franse LV, et al : Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 18 : 1149-1154, 2000.
PubMed
42) Pitts NE : The clinical evaluation of prazosin hydrochloride, a new antihypertensive agent. In : Prazosin-Evaluation of a New Hypertensive Agent (ed by Cotton DWK). p 149-163, Excerpta Medica, Amsterdam, 1974.
 
43) Stokes G, et al : Influence of dosage and dietary sodium on the first-dose effects of prazosin. Br Med J 1 : 1507-1508, 1977.
PubMed
P.172 掲載の参考文献
1) 日本循環器学会 "運動に関する診療基準委員会" (班長村山正博) : 運動負荷試験に関する診療基準 (1988年度報告), 運動療法に関する診療基準 (1989年度報告). Jpn Cire J 55 : 379-397, 1991.
 
2) 中谷矩章 : 各スタチンの常用量と脂質降下作用の比較. 薬のサイエンス 2 : 59, 1999.
Medical*Online
3) Edmundowicz D, et al : Comparing treatment success with statins : Results from the atorvastatin comparative cholesterol efficacy and safety study (ACCESS). Atherosclerosis 151 (1) : 277, 2000.
 
4) Fuster V, et al : The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 326 : 242-250, 1992.
PubMed
5) Fuster V, et al : The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 326 : 310-318, 1992.
PubMed
6) Davies MJ, et al : Risk of thrombosis in human atherosclerotic plaques : role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 69 : 377-381, 1993.
PubMed
7) Libby P : Molecular bases of the acute coronary syndromes. Circulation 91 : 2844-2850, 1995.
PubMed
8) Aikawa M, et al : Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma : a potential mechanism of lesion stabilization. Circulation 97 : 2433-2444, 1998.
PubMed
9) Aikawa M, et al : An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103 : 276-283, 2001.
PubMed
10) Fukumoto Y, et al : Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 103 : 993-999, 2001.
PubMed
11) Nakamura H, et al : MEGA Study Group : Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study) : a prospective randomised controlled trial. Lancet 368 : 1155-1163, 2006.
 
P.177 掲載の参考文献
1) 内潟安子 : 低血糖症. 内科学 (金澤一郎ほか編), p2326-2366, 医学書院, 2006.
 
2) 武藤和子ほか : ヒトインスリンアレルギーを呈した2症例. Diabetes Journal 23 : 135-139, 1995.
 
3) 吉野功二ほか : インスリン製剤中のヒトインスリンおよびプロタミンに対して全身性アレルギーをきたした糖尿病の1例. 糖尿病 42 : 927-930, 1999.
 
4) 井上篤ほか : ヒトインスリンおよびインスリンアナログ製剤に即時型局所アレルギー反応を示した2型糖尿病の1例. 糖尿病 49 : 279-285, 2006.
 
5) 有好香子ほか : アナフィラキシーショックをきたしたインスリンアレルギーの1例. 糖尿病 48 : 617-620, 2005.
 
6) Hara K, et al : Antibody-mediated insulin resistance treated by cessation of insulin administration. Intern Med 39 : 143-145, 2000.
PubMed
7) 坂本啓子ほか : インスリン抗体は血糖不安定の原因と考えられた1型糖尿病の1例. 糖尿病 47 : 471-476, 2002.
 
8) Ratner RE, et al : Persistent cutaneous insulin allergy resulting from high-molecular-weight insulin aggregates. Diabetes 39 : 728-733, 1990.
PubMed
9) Beltrand J, et al : Insulin allergy and extensive lipoatrophy in child with type 1 diabetes. Horm Res 65 : 253-260, 2006.
PubMed
10) Griffin ME, et al : Lipoatrophy associated with lispro insulin in insulin pump therapy : an old complication, a new cause? Diabetes Care 24 : 174, 2001.
PubMed
11) Ampudia-Blasco FJ, et al : A new case of lipoatrophy with lispro insulin in insulin pump therapy : is there any insulin preparation free of complications? Diabetes Care 26 : 953-954, 2003.
PubMed
12) Vardar B, Kizilci S : Incidence of lipohypertrophy in diabetic patients and a study of influencing factors. Diabetes Res Clin Pract 77 : 231-236, 2007.
 
13) http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
PubMed
P.180 掲載の参考文献
1) DeFronzo RA : Pharmacological therapy for type 2 diabetes mellitus. Ann Intern Med 131 : 281-303, 1999.
PubMed
2) Rosskamp R, et al : Clinical profile of the novel sulphonylurea glimepiride. Diabetes Res Clin Pract 31 : S33-S42, 1996.
PubMed
3) Clark HE, Matthews DR : The effect of glimepiride on pancreatic β cell function under hyperglycaemic clamp and hyperinsulinaemic clamp conditions in non-insulin-dependent diabetes mellitus. Horm Metab Res 28 : 445-450, 1996.
 
4) UK Prospective Diabetes Study (UKPDS) Group : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 : 837-853, 1998.
 
5) Inzucchi SE : Oral antihyperglycemic therapy for type 2 diabetes. JAMA 287 : 360-372, 2002 (Review).
PubMed
6) Butler AE, Butler PC : β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52 : 102-110, 2003.
 
7) Uwaifo GI, Ratner RE : Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol 99 : 51B-67B, 2007.
PubMed
8) 谷口中, 清野裕 : 経口血糖降下薬の使い分けと併用療法. 内科 91 : 97-103, 2003.
 
9) 浜崎暁洋, 山田祐一郎 : スルポニル尿素薬の適応と使用法の実際. 診断と治療 91 : 1589, 2003.
 
10) 能登谷洋子, 菊池方利 スルポニル尿素薬とグリニド薬. 内科 9757-60, 2006.
 
P.186 掲載の参考文献
1) Tominaga M, et al : Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22 : 920-924, 1999.
 
2) DECODE-study-group : Glucose tolerance and mortality : comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology : Collaborative analysis Of Diagnostic criteria in Europe. Lancet 354 : 617-621, 1999.
 
3) Chiasson JL, et al ; STOP-NIDDM Trail Research Group : Acarbose for prevention of type 2 diabetes mellitUs : the STOP-NIDDM randomized trial. Lancet 359 : 2072-2077, 2002,
 
4) Chiasson JL, et al ; STOP-NIDDM Trial Research Group : Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance : the STOP-NIDDM trial. JAMA 290 : 486-494, 2003.
 
5) van de Laar FA, et al : Alpha-glucosidase inhibitors for patients with type 2 diabetes : results from a Cochrane systematic review and meta-analysis. Diabetes Care 28 : 154-163, 2005.
PubMed
6) Piche T, et al : Acarbose and lymphocytic colitis. Lancet 356 : 1246, 2000.
PubMed
7) Masato T : Potentially lethal ileus associated with acarbose treatment for NIDDM. Diabetes Care 20 : 1210-1211, 1997.
 
8) Hayakawa T, et al : Pneumatosis cystoides intestinalis after treatment with an α-glucosidase inhibitor. Diabetes Care 22 : 366-367, 1999.
 
9) Fujimoto Y, et al : Acarbose-induced hepatic injury. Lancet 351 : 340, 1998.
PubMed
10) Carrascosa M, et al : Acarbose-induced acute severe hepatotoxicity. Lancet 349 : 698-699, 1997.
PubMed
11) Andrade RI, et al : Hepatic injury caused by acarbose. Ann Intern Med 124 : 931, 1996.
 
12) Ahr HJ, et al : Pharmacokinetics of acarbose. Part I : Absorption, concentration in plasma, metabolism and excretion after single administration of [14C] acarbose to rats, dogs and man. Arzneimittelforschung 39 : 1254-1260, 1989.
PubMed
13) 戸田剛太郎ほか : アカルボース投与例に発生した肝障害の臨床的特徴に関する検討. 臨床医薬 16 : 1047-1054, 2000.
Medical*Online
14) Masumoto T, et al : Drug-induced hepatitis with severe cholestasis due to voglibose. Intern Hepatol Commun 5 : 289-296, 1996.
 
15) 山中一彦ほか : α-グルコシダーゼ阻害薬投与中に門脈ガス血症を合併し保存的に治癒した2型糖尿病の1例. 糖尿病 46 : 745-749, 2003.
 
P.192 掲載の参考文献
1) Dormandy JA, et al ; PROactive investigators : Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial. Lancet 366 (9493) : 1279-1289, 2005.
PubMed
2) Guan Y, et al : Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11 (8) : 861-866, 2005.
PubMed
3) Hong G, et al : PPARgamma activation enhances cell surface ENaCalpha via up-regulation of SGK1 in human collecting duct cells. FASEB J 17 (13) : 1966-1968, 2003.
PubMed
4) Sotiropoulos KB, et al : Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation : novel mechanism for PPARgamma agonist's effects on edema and weight gain. FASEB J 20 (8) : 1203-1205, 2006.
PubMed
5) Shishido S, et al : Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes. Hepatology 37 (1) : 136-147, 2003.
PubMed
6) Kawamori R, et al : Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus : Postmarketing surveillance study in Japan. Diabetes Res Clin Pract 76 (2) : 229-235, 2007.
PubMed
7) 加来浩平ほか : 2型糖尿病におけるメトホルミンの使用実態に関する観察研究 (MORE study). 糖尿病 49 (5) : 325-331, 2006.
 
8) Howlett HC, Bailey CJ : A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 20 (6) : 489-503, 1999.
PubMed
9) Oates NS, et al : Genetic polymorphism of phenformin 4-hydroxylation. Clin Pharmacol Ther 32 (1) : 81-89, 1982.
PubMed
10) Caspary WF, Creutzfeldt W : Analysis of the inhibitory effect of biguanides on glucose absorption : inhibition of active sugar transport. Diabetologia 7 (5) : 379-385, 1971.
PubMed
11) Scarpello JH, et al : Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med 15 (8) : 651-656, 1998.
PubMed
P.197 掲載の参考文献
1) Nebiki H, et al : Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer. Dig Dis Sci 43 (9 Suppl) : 203S-206S, 1998.
 
2) Higuchi K, et al : Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status. Dig Dis Sci 43 (9 Suppl) : 99S-106S, 1998.
 
3) Arakawa T, et al : Indomethacin treatment during initial period of acetic acid-induced rat gastric ulcer healing promotes persistent polymorphonuclear cell-infiltration and increases future ulcer recurrence. Possible mediation of prostaglandins. Dig Dis Sci 41 : 2055-2061, 1996.
PubMed
4) 達脇大ほか : 消化性潰瘍治療薬. 臨牀と研究 83 : 1127-1133, 2006.
Medical*Online
5) Robert A, et al : Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 77 : 433-443, 1979.
PubMed
6) Kobayashi K, Arakawa T : Arachidonic acid cascade and gastric mucosal injury, protection, and healing : topics of this decade. J Clin Gastroenterol 21 (Suppl 1) : S12-17, 1995.
 
7) Tarnawski A, Arakawa T : Cytoprotection : Mechanism of mucosal protection and gastroduodenal damage. Contemp Intern Med 4 : 95-109, 1992.
 
8) Arakawa T, et al : Protection of isolated rat gastric cells by prostaglandins from damage caused by ethanol. Preliminary report. J Clin Gastroenterol 10 (Suppl 1) : S28-S34, 1988.
 
9) 中村孝司 : PG製剤の種類とその用い方. 臨床と薬物治療 6 : 505-510, 1987.
 
10) 野本昭三ほか : アルミニウム. 日本臨牀 62 (増刊号12) : 326-328, 2004.
Medical*Online
11) 太田美由希ほか : 医薬品添加物におけるアルミニウム (Al) 含有量に関する検討. 透析会誌 38 (7) : 1337-1339, 2005.
 
12) 櫻川さほりほか : テプレノンの後発医薬品で経験した副作用. 診療と新薬 43 : 1203-1207, 2006.
 
P.201 掲載の参考文献
1) 日本医薬品集 医療薬2007版 (日本医薬品集フォーラム監), じほう, 2006.
 
2) Clark DW, Srandell J : Myopathy including polymyositis : a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol 62 : 473 -479, 2006.
 
3) Youssef SS, et al : Acute pancreatitis associated with omeprazole. Int J Clin Pharmacol Ther 43 : 558-561, 2005.
PubMed
4) Vieth M, Stolte M : Fundic polyps are not induced by proton pump inhibitor therapy. Am J Clin Pathol 116 : 716-720, 2001.
 
5) Laheij RI, et al : Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 292 : 1955-1960, 2004.
 
6) Chande N, Driman DK : Microscopic colitis associated with lansoprazole : report of two cases and a review of the literature. Scand J Gastroenterol 42 : 530-533, 2007.
 
7) Kuipers EJ, et al : Long-term sequelae of Helicobacter pylori gastritis. Lancet 345 : 1525-1528, 1995.
PubMed
8) Kuipers EJ, et al : Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease : results of a randomised controlled trial. Gut 53 : 12-20, 2004.
PubMed
P.208 掲載の参考文献
1) Kawai S, et al : Recent advances in nonsteroidal anti-inflammatory drugs. Allergol Int 54 : 209-215, 2005.
 
2) Kojima F, et al : Prostaglandin E synthase in the pathophysiology of arthritis. Fundam Clin Pharmacol 19 : 255-261, 2005.
 
3) Kusunoki N, et al : Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase-2 inhibitors. Ar thritis Rheum 46 : 3159-3167, 2002.
 
4) Yamazaki R, et al : Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 531 : 278-284, 2002.
PubMed
5) Kawai S : Cyclooxygenase selectivity and the risk of gastrointestinal complications of various nonsteroidal anti-inflammatory drugs : a clinical consideration. Inflamm Res 47 (Suppl 2) : S102-S106, 1998.
 
6) 川合眞一 : 非ステロイド抗炎症薬, 鎮痛・解熱薬. 総合感冒薬. 今日の治療薬 解説と便覧2007 (水島裕編), p256-265, 南江堂, 2007.
 
7) Sakamoto C, et al : Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol 62 : 765-772, 2006.
PubMed
8) Bjorkman DJ : Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States : risk factors and frequency of complications. Am J Med 107 (6A) : 3S-10S, 1999.
PubMed
9) Silverstein FE, et al : Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis : the CLASS study : A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 : 1247-1255, 2000.
PubMed
10) Bombardier C, et al ; VIGOR Study Group : Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 : 1520-1528, 2000.
 
11) Singh G, et al ; SUCCESS-I Investigators : Celecoxib versus naproxen and diclofenac in osteoarthritis patients : SUCCESS-1 Study. Am J Med 119 : 255-266, 2006.
PubMed
12) Bresalier RS, et al ; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators : Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 : 1092-1102, 2005.
 
13) Solomon SD, et al ; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 : 1071-1080, 2005.
 
14) Bertagnolli MM, et al ; APC Study Investigators : Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 : 873-884, 2006.
 
15) Hippisley-Cox J, Coupland C : Risk of Inyocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs : population based nested case-control analysis. BMJ 330 : 1366-1369, 2005.
PubMed
P.216 掲載の参考文献
1) 薬剤性肺障害の評価, 治療についてのガイドライン (社団法人日本呼吸器学会薬剤性肺障害ガイドライン作成委員会編), p39, メディカルレビュー社, 2006.
 
2) Imokawa S, et al : Methotrexate pneumonitis : review of the literature and histopathological findings in nine patients. Eur Respir J 15 : 373-381, 2000.
PubMed
3) Kinder N, et al : The treatment of inflammatory arthritis with methotrexate in clinical practice : treatment duration and incidence of adverse drug reactions. Rheumatology 44 : 61-66, 2005.
 
4) リウマトレックスカプセル(R) 適正使用情報, Vol 11 (死亡例の検討), 2006年5月.
 
5) Saravanan V, et al : Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology 43 : 143-147, 2004.
PubMed
6) アラバ(R) 錠全例調査 (使用成績調査) Cohort A中間報告, アベンティスファーマ株式会社.
 
7) アラバ外部安全性評価委員会 特別委員会 (呼吸器分科会) 中間報告, アベンティスファーマ株式会社, 社内資料.
 
8) Akira M, et al : Drug-induced pneumonitis : thin-section CT findings in 60 patients. Radiology 224 : 852-860, 2002.
PubMed
9) Suzuki Y, et al : Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. Scand J Rheumatol 28 : 273-281, 1999.
PubMed
10) Walker AM, et al : Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 36 : 329-335, 1993.
PubMed
11) Kremer J, et al : Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 37 : 316-328, 1994.
PubMed
12) 中野正明ほか : 慢性関節リウマチにおける薬剤性腎障害. リウマチ 36 : 775, 1996.
 
13) Wolfe F, et al : Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50 : 372-379, 2004.
PubMed
14) Tohyama M, et al : Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch Dermatol 134 : 1113-1117, 1998.
PubMed
15) 鈴木康夫ほか : メトトレキサート (MTX) により誘発されるリンパ増殖性疾患. リウマチ科 28 : 498-506, 2002.
 
P.223 掲載の参考文献
1) Laura C, et al : Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 156 : 4422-4428, 1996.
 
2) 佐藤由紀夫 : 神経ベーチェット病で十分量のステロイドが必要な根拠は. EBM神経疾患の治療 2007-2008 (岡本幸市ほか編), p329-334, 中外医学社, 2007.
 
3) Stuck A, et al : Risk of infection complication in patients taking glucocorticosteroids. Rev Infect Dis 11 : 954-963, 1989.
PubMed
4) 田中良哉, 斎藤和義 : 膠原病に於ける日和見感染症とその対策. 日内会誌 93 : 1654-1659, 2004.
 
5) Adachi JD, et al : Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337 : 382-387, 1997.
PubMed
6) Nawata H, et al : Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23 : 105-109, 2005.
PubMed
7) Bulkley BH, et al : The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med 58 : 243-264, 1975.
PubMed
8) Messer J, et al : Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 309 : 21-24, 1983.
PubMed
9) 塩川優一ほか : 非ステロイド系抗炎症剤による上部消化管傷害に関する疫学調査. リウマチ 31 : 96-111, 1991.
 
10) Gunner LN, et al : Risk of hospitalization resulting from upper gastrointestinal bleeding among patients taking corticosteroids. A register-based cohort study. Am J Med 111 : 541-545, 2001.
 
11) 佐藤由紀夫 : NSAIDs潰瘍. 内科 97 : 668-671, 2006.
 
P.231 掲載の参考文献
1) 宮崎生子, 桂栄美 : 医薬品副作用被害救済制度について. 日常使用薬の注意すべき副作用. 成人病と生活習慣病 36 : 1405-1412, 2006.
 
2) 日本感染症学会, 日本化学療法学会 (編) : 抗菌薬の副作用. 抗菌薬使用のガイドライン第1版, p60-77, 協和企画, 2005.
 
3) 齋藤厚ほか : 社団法人日本化学療法学会臨床試験委員会皮内反応検討特別部会報告書. 日本化学療法学会雑誌 51 : 497-506, 2003.
 
4) Andes DR, Craig WA : Cephalosporins. In : Principles and Practice of Infectious Diseases, 6th ed (ed by Mandell D, et al), p 294-311, Churchill Livingstone, Philadelphia, 2005.
 
5) Gilbert DN, et al : The Sanford Guide to Antimicrobial Chemotherapy 2006, 36th ed (ed by Gilbert DN, et al), p 132-148, Antimicrobial Therapy, Sperryville, 2006.
 
6) 斧康雄 : 抗菌薬の特性と投与法. 日内会誌 95 : 2183-2187, 2006.
 
7) 斧康雄, 国井乙彦 : 薬剤別. プリンシパル抗生剤の使い方 (国井乙彦編著), p14-77, 日本医事新報社, 1993.
 
P.239 掲載の参考文献
1) Moscona A : Neuraminidase inhibitors for influenza. N Engl J Med 353 : 1363-1373, 2005.
PubMed
2) The panel on clinical practices for treatment of HIV infection convened by the Department of Health and Human Services : Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November 10, 2003. http://AIDSinfo.nih.gov
 
P.245 掲載の参考文献
1) 村崎光邦 : 抗不安薬開発の歴史と展望. 臨床精神薬理 6 : 671-688, 2003.
 
2) Vyas I, Carney MWP : Diazepam withdrawal fits. Br Med J 4 : 44, 1975.
 
3) 辻敬一郎, 田島治 : ベンゾジアゼピンの依存と離脱症状. 臨床精神医学 35 : 1669-1674, 2006.
Medical*Online
4) 井澤志名野 : ベンゾジアゼピン系薬剤の依存性について. 精神科治療学 19 : 1319-1325, 2004.
 
5) Stahl SM : Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry 63 : 756-757, 2002.
 
6) Stahl SM : Essential psychopharmacology. In : Neuroscientific Basis and Practical Applications, 2nd ed, Cambridge University Press, Cambridge, 2000. (仙波純一 (訳) : 精神薬理エセンシャルズ. 神経科学的基礎と応用, 第2版, メディカル・サイエンス・インターナショナル, 2002.)
 
7) 高瀬勝教ほか : ベンゾジアゼピンが認知・運動機能に及ぼす影響. 臨床精神医学 35 : 1653-1658, 2006.
Medical*Online
8) 押淵英弘ほか : ベンゾジアゼピンと記憶障害. 臨床精神医学 35 : 1659-1662, 2006.
Medical*Online
9) 上田幹人, 下田和孝 : ベンゾジアゼピンの奇異反応. 臨床精神医学 35 : 1663-1666, 2006.
Medical*Online
10) Stahl SM : Essential psychopharmacology. In : The Prescriber's Guide, Cambridge University Press, Cambridge, 2005. (仙波純一 (訳) : 精神科治療薬処方ガイド, メディカル・サイエンス・インターナショナル, 2006.)
 
P.253 掲載の参考文献
1) Schneider LS, et al : Risk of death with atypical antipsychotic drug treatment for dementia : meta-analysis of randomized placebo-controlled trials. JAMA 294 : 1934-1943, 2005.
PubMed
2) Wang PS, et al : Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353 : 2335-2341, 2005.
PubMed
3) Dubicka B, et al : Suicidal behaviour in youths with depression treated with new-generation antidepressants : meta-analysis. Br J psychiatry 189 : 393-398, 2006.
PubMed
4) Hammad TA, et al : Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63 : 332-339, 2006.
PubMed
5) Kallen B : Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pedi-atr Adolesc Med 158 : 312-316, 2004.
 
6) Hallberg P, Sjoblom V : The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding : a review and clinical aspects. J Clin Psychopharmacol 25 : 59-73, 2005.
PubMed
7) Hemels ME, et al : Antidepressant use during pregnancy and the rates of spontaneous abortions : a meta-analysis. Ann Pharmacother 39 : 803-809, 2005.
PubMed
8) Wogelius P, et al : Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 17 : 701-704, 2006.
PubMed
9) Therapeutic Goods Administration. Safeguarding public health & safety in Australia by regulating medicines, medical devices, blood & tissues. Information for health professionals concerning use of SSRI antidepressants in pregnant women. http://www.tga.health.gov.au/alerts/ssri-hp.htm
 
10) Chambers CD, et al : Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 354 : 579-587, 2006.
PubMed
11) Cohen LS, et al : Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295 : 499-507, 2006.
 
P.258 掲載の参考文献
1) 厚生省免疫・アレルギー研究班 : 喘息予防・管理ガイドライン2006, 協和企画, 2006.
 
2) Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention : NHI publication 02-3659 report. Updated 2005. http://www.ginasthma.com
 
3) Wurthwein G, et al : Lipophilicity and receptor affinity of glucocorticoids. Pharm Ztg Wiss 4 : 161-167, 1992.
 
4) Meibohm B, et al : The clinical phamacology of fluticasone propionate. Rev Contemp Phannacother 9 : 535-549, 1998.
 
5) Daley-Yates PT, et al : Beclomethasone dipropionate : absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 51 : 400-409, 2001.
PubMed
6) 足立満, 美濃口健治 : 成人喘息患者に対する吸入ステロイド薬の副腎皮質機能への影響. 日呼吸会誌 44 : 151-159, 2006.
Medical*Online
7) Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 343 : 1054-1063, 2000.
 
8) Norjavaara E, de Verdier MG : Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol 111 : 736-742, 2003.
 
9) Aaronson D, et al : Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitaryadrenal axis in asthmatic subjects : a dose-response study. J Allergy Clin Immunol 101 : 312-319, 1998.
 
10) Thompson PJ, et al : Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol. Respir Med 92 (Suppl A) : 33-39, 1998.
 
11) Li JT, et al : Fluticasone propionate powder and lack of clinically significant effects on hypothalamicpituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol 103 : 1062-1068, 1999.
 
12) Li JT, et al : Effects of fluticasone propionate, triamcinolone acetonide, prednisone, and placebo on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol 103 : 622 -629, 1999.
 
13) Todd GR, et al : Survey of adrenal crisis associated with inhaled conicosteroids in the United Kingdom. Arch Dis Child 87 : 457-461, 2002.
PubMed
P.266 掲載の参考文献
1) 牧野荘平ほか (監) : 薬物によるコントロール. 喘息予防・管理ガイドライン2003, JGL 1998改訂2版, p71-124, 協和企画, 2003.
 
2) 平島由香ほか : ケミカルメディエーター遊離抑制薬 (インタール, リザベン). medicina 39 : 169-172, 2002.
 
3) Konig P : The effects of cromolyn sodium and nedocromil sodium in early asthma prevention. J Allergy Clin Immunol 105 : S575-581, 2000.
PubMed
4) 栗原和幸ほか : 重症喘息児のexercise-induced asthma (EIA) に対するSCG, Ipratropium bromideの単独および併用効果. 小児科臨床 45 : 203-207, 1993.
 
5) 有田昌彦 : 食物アレルギー患児に対するdisodium cromoglycate経口剤の長期使用経験 アトピー性皮膚炎を中心に. 小児科臨床 39 : 1152-1164, 1986.
Medical*Online
P.271 掲載の参考文献
1) 藤澤隆夫 抗ヒスタミン薬の多彩な薬理作用. アレルギー・免疫 12 : 257-262, 2005.
 
2) Leurs R, et al : H1-antihistamines : inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 32 : 489-498, 2002.
PubMed
3) Timmerman H : Why are non-sedating antihistamines non-sedating? Clin Exp Allergy 29 (Suppl 3) : 13-18, 1999.
 
4) Yanai K, et al : Positron emission tomographic study of central histamine H1-receptor occupancy in human subjects treated with epinastine, a second-generation antihistamine. Methods Find Exp Clin Pharmacol 17 (Suppl C) : 64-69, 1995.
 
5) 谷内和彦ほか : フェキソフェナジン 中枢に移行しない第二世代抗ヒスタミン薬. Molecular Medicine 41 (8) : 1008-1015, 2004.
 
6) Tagawa M, et al : Relationship between effects of alcohol on psychomotor performances and blood alcohol concentrations. Jpn J Pharmacol 83 : 253-260, 2000.
PubMed
7) 新島新一 : 抗ヒスタミン薬の小児における使用実態-インターネット患者意識調査から-. アレルギー・免疫 12 : 292-300, 2005.
 
8) Yokoyama H, et al : Proconvulsive effects of histamine H1-antagonists on electrically-induced seizure in developing mice. Psychopharmacology 112 : 199-203, 1993.
PubMed
9) 佐藤一樹ほか : 抗アレルギー薬. 小児科 47 : 769-773, 2006.
 
10) 畔取康浩ほか : 気管支喘息, アレルギー性鼻炎, 蕁麻疹, 湿疹・皮膚炎, 皮膚掻痒症, 痒疹ならびに掻痒を伴う尋常性乾癬の疾患領域におけるアレジオン錠 (塩酸エピナスチン) の市販後調査-使用成績調査-. 新薬と臨床 54 : 495-539, 2005.
 
11) Holgate ST, et al ; Consensus Group on New-Generation Antihistamines : Consensus Group on New-Generation Antihistamines (CONGA) : present status and recommendations. Clin Exp Allergy 33 (9) : 1305-1324, 2003.
 
P.276 掲載の参考文献
1) 和泉孝志 喘息とロイコトリエン拮抗薬 : 最近の知見-基礎から臨床へ-. 日本胸部臨床 58 (6) : 385-392, 1999.
 
2) 藤井和彦, 興椙博次 : ロイコトリエン拮抗薬. 日本胸部臨床 65 (4) : 334-345, 2006.
 
3) 下田照文ほか : 喘息治療の新しい動向 ロイコトリエン拮抗薬. 診断と治療 89 (12) : 2213-2216, 2001.
 
4) 社団法人日本アレルギー学会喘息ガイドライン専門部会 (監) : 喘息予防・管理ガイドライン2006, 協和企画, 2006.
 
5) 岡田正人 : レジデントのためのアレルギー疾患診療マニュアル, 医学書院, 2006.
 
6) 蝶名林直彦ほか : ロイコトリエン拮抗薬 (オノン, アコレート, シングレア, キプレス). medicina 39 (11増刊号) : 177-179, 2002.
 
7) 田村弦 : 抗ロイコトリエン薬. クリニカ 30 (2) : 41-46, 2003.
 
8) Kinoshita M, et al : Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast. J Allergy Clin Immunol 103 : 534-535, 1999.
 
9) Knoell DL, et al : Churg-Strauss syndrome associated with zafirlukast. Chest 114 : 332-334, 1998.
PubMed
10) 坂口基ほか : アレルギー性肉下腫性血管炎 (Churg Strauss syndrome : CSS) の臨床的検討. アレルギー 50 (4) : A371, 2001.
 
P.280 掲載の参考文献
1) 大田健 : 炎症性メディエーター. 日内会誌 85 : 178-183, 1996.
 
2) 宮本昭正ほか : OKY-046の成人気管支喘息に対する臨床検討-多施設二重盲検法による検討・用量検討試験. 医学のあゆみ 154 : 385-406, 1990.
 
3) 中島重徳ほか : トロンボキサンA2受容体拮抗薬AA-2414の成人気管支喘息に対する臨床検討-多施設二重盲検法による至適用量設定試験-. 臨床医薬 9 (Suppl 8) : 101-137, 1993.
 
4) Fujimura M, et al : Eosinophilic tracheobronchitis and airway cough hypersensitivity in chronic non-productive cough. Clin Exp Allergy 30 : 41-47, 2000.
PubMed
5) 新井秀宣ほか : 気道リモデリングと気道過敏性の関連についての検討. 臨床呼吸生理 33 : 105-108, 2000.
 
6) 金子富志人, 大田健 : 抗アレルギー薬. 臨床医 27 (5) : 28-31, 2001.
 
7) 大田健, 星野恵津夫 : 我国の薬剤性肺炎とインターフェロン間質性肺炎. 内科 77 : 698-702, 1996.
 
8) Ueda T, et al : Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 146 : 266-268, 1992.
PubMed
9) 平松久仁子, 臼杵次郎 : 薬剤性肺障害・呼吸器疾患に対する日本人の遺伝的感受性. LUNG perspective 14 : 36-40, 2006.
 
10) Tabata C, et al : All-trans-retinoic acid prevents radiation-or bleomycin-induced pulmonary fibrosis. Am J Respir Crit Care Med 174 : 1352-1360, 2006.
 
11) Carey MA, et al : Spontaneous airway hyperresponsiveness in estrogen recepter-α-deficient mice. Am J Respir Crit Care Med 175 : 126-135, 2007.
 
12) Shinagawa K, et al : Coagulation factor Xa modlllates airway remodeling in a murine model of asthma. Am J Respir Crit Care Med 175 : 136-143, 2007.
 
13) Sakai T, et al : Hepatocyte growth factor in bronchoalveolar lavage fluids and cells in patients with inflammatory chest diseases of the lower respiratory tract : detection by RIA and in situ hybridization. Am J Respir Cell Mol Biol 16 : 388-397, 1997.
PubMed
P.286 掲載の参考文献
1) Hesketh PJ, et al : Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39 (8) : 1074-1080, 2003.
PubMed
2) Kris MG, et al : American Society of Clinical Oncology guideline for antiemetics in oncology : update 2006. J Clin Oncol 24 (18) : 2932-2947, 2006.
 
3) Lindquist SF, et al : Effect of oral hygiene on stomatitis in patients receiving cancer chemotherapy. J Prosthet Dent 40 (3) : 312-314, 1978.
PubMed
4) Elting LS, et al : The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98 (7) : 1531-1539, 2003.
 
5) Mead GM : Management of oral mucositis associated with cancer chemotherapy. Lancet 359 (9309) : 815-816, 2002.
PubMed
6) Finch PW, Rubin JS : Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair. Adv Cancer Res 91 : 69-136, 2004.
PubMed
7) Spielberger R, et al : Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351 (25) : 2590-2598, 2004.
PubMed
8) Rosen LS, et al : Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 24 (33) 15194-5200, 2006.
 
9) Benson AB, et al : Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22 (14) : 2918-2926, 2004.
PubMed
10) Ando Y, et al : Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity : a pharmacogenetic analysis. Cancer Res 60 (24) : 6921-6926, 2000.
PubMed
P.291 掲載の参考文献
1) Hughes WT, et al : 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34 : 730-751, 2002.
PubMed
2) Masaoka T : Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan : executive summary. Clin Infect Dis 39 (Suppl 1) : S49-52, 2004.
 
3) Smith TJ, et al : 2006 update of recommendations for the use of white blood cell growth factors : an evidence-based clinical practice guideline. J Clin Oncol 24 : 3187-3205, 2006.
PubMed
4) 日本癌治療学会臨床試験委員会 : 日本癌治療学会G-CSF適正使用ガイドライン. Int J Clin Oncol 6 (4) : 1-24, 2001.
 
5) Bodey GP, et al : Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64 : 328-340, 1966.
PubMed
6) Klastersky J, et al : The Multinational Association for Supportive Care in Cancer risk index : A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18 : 3038-3051, 2000.
PubMed
7) Paul M, et al : Empirical antibiotics against Gram-positive infections for febrile neutropenia : systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 55 : 436-444, 2005.
PubMed
8) 川村和夫 : II. 特殊病態における抗菌化学療法 3. 顆粒球減少症患者. 日内会誌 95 : 38-43, 2006.
 
9) Hartmann LC, et al : Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 336 : 1776-1780, 1997.
PubMed
10) Bucaneve G, et al : Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353 : 977-987, 2005.
PubMed
11) Gafter-Gvili A, et al : Meta-analysis : antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 142 : 979-995, 2005.
PubMed
12) Schiffer CA, et al ; American Society of Clinical Oncology : Platelet transfusion for patients with cancer : clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 : 1519-1538, 2001.
 
13) Rizzo JD, et al ; American Society of Clinical Oncology. American Society of Hematology : Use of epoetin in patients with cancer : evidence-based clinical practice guidelines of the American Society of Clinical Oncology and The American Society of Hematology. J Clin Oncol 20 : 4083-4107, 2002.
 
P.298 掲載の参考文献
1) Weiss RB : Hypersensitivity reactions. Semin Oncol 19 : 458-477, 1992.
 
2) Stone HD Jr, et al : Hypersensitivity reactions to Escherichia coli-derived polyethylene glycolated-asparaginase associated with subsequent immediate skin test reactivity to E. coli-derived granulocyte colony-stimulating factor. J Allergy Clin Immunol 101 : 429-431, 1998.
 
3) Evans WE, et al : Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 49 : 1378-1383, 1982.
PubMed
4) Alley E, et al : Cutaneous toxicities of cancer therapy. Curr Opin Oncol 14 : 212-216, 2002.
PubMed
5) Nagore E, et al : Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 1 : 225-234, 2000.
PubMed
6) Susser WS, et al : Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 40 : 367-398, 1999.
PubMed
7) Larson DL : What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg 75 : 397-405, 1985.
PubMed
8) 石原和之, 山本明史 : 抗がん剤の血管外漏出とその対策-特に皮膚障害について- (改訂版), 協和発酵, 2003.
 
9) Dorr VJ : A practitioner's guide to cance卜related alopecia. Semin Oncol 25 : 562-570, 1998.
 
10) Rodriguez R, et al : Minoxidil (Mx) as a prophylaxis of doxorubicin-induced alopecia. Ann Oncol 5 : 769-770, 1994.
PubMed
11) Duvic M, et al : A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol 35 : 74-78, 1996.
 
P.303 掲載の参考文献
1) Cooper JA, et al : Drug-induced pulmonary disease. Part 1 : Cytotoxic drugs. Am Rev Respir Dis 133 : 321-340, 1986.
PubMed
2) Lombard MC : Drug-induced pulmonary disease. In : Pathology of Pulmonary Disease (ed by Saldana MJ), p 149-157, JB Lippincott, Philadelphia, 1994.
 
3) Myers JL : Pathology of drug-induced lung disease. In : Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease, 3rd ed (ed by Katzenstein AA), p81-111, WB Saunders, Philadelphia, 1997.
 
4) 薬剤性肺障害の評価, 治療についてのガイドライン (社団法人日本呼吸器学会薬剤性肺障害ガイドライン作成委員会編), 2006.
 
5) Muller NL, et al : Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 91 : S24-30, 2004.
PubMed
6) Seo Y, et al : Beneficial effect of polymyxin B-immobilized fiber column (PMX) hemoperfUsion treatment on acute exacerbation of idiopathic pulmonary fibrosis. Intem Med 45 (18) : 1033-1038, 2006.
 
7) 一瀬幸人ほか : ゲフィチニブのコホート内ケースコントロールスタディ ILDの相対リスクおよび危険因子を検討. 肺癌 (第47回日本肺癌学会総会総会号), S2-6, 2006.
 
8) Miyakoshi S, et al : Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 107 (9) : 3492-3494, 2006.
PubMed
9) Gotoh A, et al : Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan : a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology. Int J Hematol 84 (5) : 406-412, 2006.
PubMed
10) ゲフィチニブ (イレッサ(R)錠250) の急性肺障害・間質性肺炎 (ILD) に関する専門家会議最終報告 (2003. 3), アストラゼネカ株式会社.
 
11) イレッサ(R)錠250プロスペクティブ調査 (特別調査) に関する結果と考察 (2004. 8), アストラゼネカ株式会社.
 
12) 弦間昭彦ほか : 特定使用成績調査間質性肺炎判定委員会 : TS-1特定使用成績調査 (間質性肺炎) の検討結果について. 日本癌治療学会学会誌, 平成18年日本癌治療学会総会, 2006.
 
13) ベルケイド適正使用ガイド, ヤンセンファーマ株式会社, 2006.
 
P.310 掲載の参考文献
1) Black DM, et al : Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 : 1535-1541, 1996.
PubMed
2) Harris ST, et al : Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282 : 1344-1352, 1999.
PubMed
3) McClung MR, et al : Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344 : 333-340, 2001.
PubMed
4) Peter CP, et al : Esophageal irritation due to alendronate sodium tablets : Possible mechanisms. Dig Dis Sci 43 : 1998-2002, 1998.
PubMed
5) Karam SM : Lineage commitment and maturation of epithelial cells in the gut. Front Biosci 4 : D286-D298, 1999.
PubMed
6) The Alendronate Once-Weekly Study Group : Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17 : 1988-1996, 2002.
 
7) Migliorati CA, et al : Bisphosphonate-associated osteonecrosis : a long term complication of bisphosphonate treatment. Lancet Oncol 7 : 508-514, 2006.
PubMed
8) Khamaisi M, et al : Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 92 : 1172-1175, 2007.
PubMed
9) Barrett-Connor E, et al : Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 : 125-137, 2006.
PubMed
10) Cummings SR, et al : The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 281 : 2189-2197, 1999.
PubMed
11) Barrett-Connor E, et al : Raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287 : 847-857, 2002.
PubMed
12) Writing Group for the Women's Health Initiative Investigators : Risks and benefits of estrogen in healthy postmenopausal women : principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 : 321-333, 2002.
 
13) Shane E, et al : Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350 : 767-776, 2004.
PubMed

III 副作用各論 - 重大な副作用 -

P.317 掲載の参考文献
1) 笹本和宏ほか : 小児における薬物過敏症. 第1編外来患児におけるアンケートでの実態調査. 日本小児アレルギー学会誌 9 : 76-82, 1998.
 
2) 鈴木修一ほか : 薬物過敏反応-15年を隔てたアンケート調査結果-アレルギー疾患は増えているか. 調査結果と原因 (宮本照正編), p37-41, 国際医学出版, 1987.
 
3) 村中正治ほか : 薬物による過剰免疫 ((4)) 多剤併用とアレルギー性薬物反応. 月刊薬事 40 : 1313-1322, 1998.
 
4) Lazarou J, et al : Incidence of adverse drug reactions in hospitalized patients : a meta-analysis of prospective studies. JAMA 279 : 1200-1205, 1998.
PubMed
5) Rudolph AH, Price EV : Penicillin reactions among patients in venereal disease clinics. A National survey. JAMA 223 : 499-501, 1973.
PubMed
6) 村中正治ほか : β-ラクタム系薬の抗原性. β-ラクタム系薬 (上田泰, 清水喜八郎編), p86-95, 南江堂, 1987.
 
7) 鈴木五男 : 薬物アレルギー. 日本醫事新報 3917 : 37-44, 1999.
Medical*Online
8) 鈴木五男 : ワクチン接種時のアナフィラキシーに対する対応-予防法と治療法-. 小児科 38 : 1529-1538, 1997.
 
P.321 掲載の参考文献
1) Hollenberg SM : Pharmacologic circulatory support. In : Surgical Intensive Care (ed by Shires GT, Barie PL), p 417-451, Little Brown, Boston, 1993.
 
2) 鈴木修二 : ショック (アナフィラキシー症状またはアナフィラキシー様症状). 薬の副作用チェックマニュアル, 第2版 (高橋隆一編), p24-32, 中外医学社, 1998.
 
3) 梅田悦生 : ショックとアナフィラキシー. 症状からひく薬の副作用, p9-28, 中外医学社, 2003.
 
4) Benowitz NL, et al : Drug in the critically ill. In : Avery's Drug Treatment, 4th ed (ed by Speight TM, Holford HG), p 513-549, Adis International, Auckland, 1997.
 
5) Tang AW : A practical guide to anaphylaxis. Am Fam Physician 68 : 1325-1332, 2003.
PubMed
6) Maddox TG : Adverse reactions to contrast material : recognition, prevention, and treatment. Am Fam Physician 66 : 1229-1234, 2002.
PubMed
7) Brady WJ, et al : Multiphasic anaphylaxis : an uncommon event in the emergency department. Acad Emerg Med 4 : 193-197, 1997.
PubMed
P.325 掲載の参考文献
1) Rubin RL : Drug-induced lupus. Toxicology 209 : 135-147, 2005.
PubMed
2) Pramatarov KD : Drug-induced lupus erythematosus. Clin Dermatol 16 : 367-377, 1998.
PubMed
3) De Rycke L, et al : Antinuclear antibodies following infli) dmab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 48 : 1015-1023, 2003.
 
4) De Bandt M, et al : Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy ; a French national survey. Arthritis Res Ther 7 : R545-R551, 2005.
PubMed
5) 武井修治 : 自己免疫症状. 小児科 47 : 684-689, 2006.
 
6) Olsen NJ : Drug-induced autoimmunity. Best Pract Res Clin Rheumatol 18 : 677-688, 2004.
PubMed
7) 天野宏一, 竹内勤 : 薬剤誘発性ループス. 別冊日本臨牀 免疫症候群 (上), p491-493, 日本臨牀社, 2000.
 
P.330 掲載の参考文献
1) 向田圭子, 弓削孟文 : 臨床症状-疫学. 悪性高熱症 (菊地博達編), p67-72, 克誠堂出版, 2006.
 
2) 松井一幸, 菊地博達 : 体温 (体温下降, 悪性高熱症). 最新麻酔科学 (稲田 豊ほか編), p1639-1645, 克誠堂出版, 1995.
 
3) Endo M, et al : Changes in the Ca-induced Ca release mechanism in the sarcoplasmic reticulum of the muscle from a patient With malignant hyperthermia. Biomed Res 4 : 83-92, 1983.
 
4) Endo M, et al : Calcium induced release of calcium from the sarcoplasmic reticulum of skinned skeletal muscle fibres. Nature 228 : 34-36, 1970.
PubMed
5) 菊地博達 : 悪性高熱症の発症機序・検査法と治療. 日本醫事新報 3812 : 11-16, 1997.
Medical*Online
6) 前原康宏ほか : わが国の悪性高熱症の集計 (1991年). 麻酔と蘇生 28 (別冊) : 79-83, 1991.
 
7) 市原靖子 : 治療-急性期, 素因者の麻酔-. 悪性高熱症 (菊地博達編), p153-162, 克誠堂出版, 2006.
 
P.334 掲載の参考文献
1) 山脇成人 : 悪性症候群 : 病態・診断・治療, 新興医学出版社, 1989.
 
2) Kawanishi C, et al : Phamlacogenetic aspects of neuroleptic malignant syndrome. Curr Pharmacogenomics 4 : 113-119, 2006.
 
3) Kawanishi C, et al : Neuroleptic malignant syndrome in cancer treatment. Palliative Support Care 3 : 51-53, 2005.
 
4) Caroff SN, Mann SC : Neuroleptic malignant syndrome. Med Clin North Am 77 : 185-202, 1993.
PubMed
5) Adityanjee, et al : Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol 22 : 151-158, 1999.
PubMed
6) 山脇成人 : 悪性症候群の病態に関する考察 : dantroleneが有効であった3症例から. 精神科治療学 1 : 413-422, 1985.
 
7) Gurrera R : Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry 156 : 169-180, 1999.
PubMed
8) Itoh H, et al : Malignant neuroleptic syndrome : its present status in Japan and clinical problems. Folia Psychiatr Neurol Jpn 31 : 565-576, 1977.
 
9) 井上雄一ほか : 水中毒と悪性症候群の関係について. 精神医学 37 : 1063-1070, 1995.
 
10) Kato D, et al : Neuroleptic malignant syndrome and polymorphisms of CYP2D6 gene. Eur J Clin Pharmacol (in press)
 
11) Ananth J, et al : Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 65 : 464-470, 2004.
PubMed
12) Pope GH, et al : Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J psychiatry 143 : 1227-1233, 1986.
 
13) DSM-IV精神疾患の診断・統計マニュアル (高橋三郎ほか訳), 医学書院, 1996.
 
14) 岩淵潔ほか : Purkinje細胞-小脳遠心路系障害および筋原性筋萎縮を呈した悪性症候群の2剖検例. 神経研究の進歩 33 : 674-676, 1989.
 
15) Miyaoka H, et al : Diazepam-responsive neuroleptic malignant syndrome : adiagnostic subtype? Am J Psychiatry 154 : 882, 1997.
 
16) Nisijima K, et al : Intravenous injection of levodopa is more effective than dantrolene as therapy for neuroleptic malignant syndrome. Biol Psychiatry 41 : 913-914, 1997.
PubMed
P.340 掲載の参考文献
1) Budnitz DS, et al : National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296 : 1858-1866, 2006.
PubMed
2) 池田美智子, 南光弘子 : 皮膚粘膜眼症候群 (Stevens-Johnson syndrome) と中毒性表皮壊死症 (toxic epidermal necrolysis). Pharmavision 8 : 37-42, 2004.
 
3) Bastuji-Garin S, et al : Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129 : 92-96, 1993.
PubMed
4) 医薬品による重篤な皮膚障害について. 医薬品・医療用具等安全性情報No, 163, 厚生省医薬安全局 (2000年11月).
 
5) 渡辺秀晃ほか : Stevens-Johnson症候群 (SJS). 皮膚科診療プラクティス19巻 (塩原哲夫ほか編), p43-48, 文光堂, 2006.
 
6) Viard I, et al : Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282 : 490-493, 1998.
PubMed
7) Abe R, et al : Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J pathol 162 : 1515-1520, 2003.
PubMed
8) 相原道子 : 薬疹の検査法update-リンパ球刺激試験. 医学のあゆみ 220 : 875-878, 2007.
Medical*Online
9) 渡辺秀晃 : 重症型薬疹の最新治療. 医学のあゆみ 220 : 902 -906, 2007.
 
10) 長村蔵人ほか : 重篤な眼病変を伴ったが, 全身療法・眼科的局所療法により失明を免れたStevens-Johnson syndrome進展型toxic epidermal necrolysisの1例. 日皮アレルギー 14 : 108-113, 2006.
Medical*Online
11) 渡辺秀晃, 飯島正文 : 薬物アレルギー防止と薬剤師の役割-スティーブンス・ジョンソン症候群への対応を中心に-. 日本薬剤師会雑誌 59 : 71-75, 2007.
 
12) 飯島正文 : 重症型薬疹. 最新皮膚科学大系, 第5巻 (玉置邦彦ほか編), p36-55, 中山書店, 2004.
 
P.343 掲載の参考文献
1) 橋本公二 : Stevens-Johnson症候群, toxic epidermal necrolysis (TEN) とhypersensitivity syndromeの診断基準および治療指針の研究 厚生科学特別研究事業 平成17年度総括研究報告, 2005.
 
2) Kano Y, et al : Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol 140 : 183-188, 2004.
PubMed
3) Tohyama M, et al : Association of human herpesvirus-6 reactivation with the fiaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol (submitted)
 
4) Shear NH, Spielberg SP : Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 82 : 1826-1832, 1988.
 
5) Shear NH, et al : Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 105 : 179-184, 1986.
PubMed
6) Hung SI, et al : HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 102 : 4134-4139, 2005.
PubMed
7) Fujino Y, et al : Human herpesvirus 6 encephalitis associated with hypersensitivity syndrome. Ann Neurol 51 : 771-774, 2002.
PubMed
8) Masaki T, et al : Human herpes virus 6 encephalitis in allopurinol-induced hypersensitivity syndrome. Acta Derm Venereol 83 : 128-131, 2003.
PubMed
9) Sekine N, et al : Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome. JAMA 285 : 1153-1154, 2001.
 
P.348 掲載の参考文献
1) 秀道広 : 蕁麻疹型薬疹. 薬疹, 中毒疹 (玉置邦彦編), p115-120, 中山書店, 2004.
 
2) 堀川達也 : 蕁麻疹型薬疹. 薬疹を極める (塩原哲夫編), p 181-186, 文光堂, 2006.
 
3) 高路修 : 蕁麻疹を治す薬とおこす薬. 皮膚アレルギーフロンティア 2 : 25-29, 2004.
 
4) 原田晋 : 蕁麻疹を増悪させる薬剤. 薬疹を極める (塩原哲夫編), p187-192, 文光堂, 2006.
 
5) 福田知雄, 塩原哲夫 : 塩酸ミノサイクリンによる蕁麻疹型薬疹. Visual Dermatology 1 : 252 -253, 2002.
 
6) 福田英三, 福田英嗣 : 薬疹 最近の傾向. 日皮会誌 116 : 1563-1568, 2006.
 
7) 南光弘子 : 本邦における有害薬物反応 (ADR) と重症薬疹-過去5年間に認定された皮膚障害の概要-. 日皮会誌 115 : 1155-1161, 2005.
 
8) Cousin F : Drug-induced urticaria. Eur J Dermatol 11 : 181-187, 2001.
PubMed
9) Sanchez-Borges M, et al : Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 95 : 154-158, 2005.
PubMed
10) Inomata N, et al : Safety of selective cyclooxygenese-2 inhibitors and a basic non-steroidal anti-inflammatory drug (NSAID) in Japanese patients with NSAID-induced urticaria and/or angioedema : Comparison of meloxicam, etodolac and tiaramide. J Dermatol 34 : 172-177, 2007.
PubMed
11) Harada S, et al : Aspirin enhances the induction of type I allergic symptoms when combined with foods and exercise in patients with food-dependent exercise-induced anaphylaxis. Br J Dermatol 145 : 336-339, 2001.
PubMed
12) Matsuo H, et al : Exercise and aspirin increase levels of circulating gliadin peptides in patients with wheat-dependent exercise-induced anaphylaxis. Clin Exp Allergy 35 : 461-466, 2005.
PubMed
13) Yap LM, et al : Drug-induced solar urticaria due to tetracycline. Australas J Dermatol 41 : 181-184, 2000.
PubMed
14) 狩野葉子 : フルオレセイン注射後に急激に出現した蕁麻疹. Visual Demlatology 1 : 250-251, 2002.
 
15) 高橋さなみほか : イオメプロールによる遅発性アレルギー性薬疹の3例. 臨床皮膚科 55 : 766-769, 2001.
 
16) 小倉香奈子ほか : 蕁麻疹型薬疹の統計 なぜ投与6, 7日目の発症がないのか? 皮膚の科学 4 : 104-110, 2005. '
 
P.352 掲載の参考文献
1) 堀尾武 : 光アレルギー/光線過敏症の基礎. アレルギー科 2 : 189-196, 1996.
 
2) Epstein S : Photoallergy and primary photosensitivity to sulfanilamide. J Invest Dermatol 2 : 43-51, 1939.
 
3) 堀尾武 : 薬物性光アレルギー. アレルギー科 5 : 572-577, 1998.
 
4) 上出良一 : 光線過敏症の診かた. Visual Dermatol 2 : 422-425, 2003.
 
5) Horio T : Photoallergic reaction. Classification and pathogenesis. Int J Dermatol 23 : 376-382, 1984.
PubMed
6) 堀尾武 : 光アレルギー. 綜合臨牀 52 : 471-475, 1993.
 
7) Schwarz K, Schwarz-Speck M : Experimentelle Untersuchungen zur Frage der Photoallergie der Sulfanilamide. Dermatologica 114 : 232-243, 1958.
 
8) Willis I, Kligman AM : The mechanism of photoallergic contact dermatitis. J Invest Dermatol 51 : 378-384, 1968.
PubMed
9) Horio T : Chlorpromazine photoallergy. Coexistence of immediate and delayed type. Arch Dermatol 111 : 1469-1471, 1975.
PubMed
10) 堀尾武, 宮内洋子 : ニューキノロン剤と光線過敏症. 日本光医学・光生物学会薬剤師会雑誌 47 : 7-11, 1995.
 
11) Horio T, et al : Phototoxicity and photoallergenicity of quinolones in guinea pigs. J Dermatol Sci 7 : 130-135, 1994.
PubMed
12) 堀尾武ほか : 非ステロイド系消炎鎮痛剤による光アレルギーの臨床と動物実験. 新薬と臨床 53 : 702-711, 2004.
Medical*Online
13) 橋本洋子 : 光パッチテストと内服照射テスト. 光線過敏症, 第3版 (市橋正光, 堀尾武編), p252-261, 金原出版, 2002.
 
P.356 掲載の参考文献
1) Cugno M, et al : Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 3 : 311-317, 2003.
PubMed
2) Sanchez-Borges M, et al : Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs. Clin Rev Allergy Immunol 24 : 125-136, 2003.
PubMed
3) Messerli FH, Nussberger J : Vasopeptidase inhibition and angio-oedema. Lancet 356 : 608-609, 2000.
PubMed
4) Sabroe RA, Black AK : Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema. Br J Dermatol 136 : 153-158, 1997.
PubMed
5) Brown NJ, et al : Recurrent angiotensin converting enzyme inhibitor-associated angioedema. JAMA 278 : 232-233, 1997.
PubMed
6) Gigli I, Rosen FS : Angioedema associated with complement abnormalities. In Fitzpatrick's Dermatology in General Medicine (ed by Freedberg IM, et al), p 1139-1143, McGraw-Hill, New York, 2003.
 
P.360 掲載の参考文献
1) Ozaki S, Wada K : Characteristics of methylphenidate dependence syndrome in psychiatric hospital settings. Nihon Arukoru Yakubutsu Igakkai Zasshi 41 (2) : 89-99, 2006.
PubMed
2) Laux G, Puryear DA : Benzodiazepines-misuse, abuse and dependency. Am Fam Physician 30 (5) : 139-147, 1984.
PubMed
3) 井澤志名野ほか : ベンゾジアゼピン系薬物の使用原則と臨床用量依存の診断と治療. アルコール・薬物関連障害の診断・治療ガイドライン, p207-222, じほう, 2003.
 
4) 尾崎茂, 和田清 : 睡眠薬乱用・依存の実態と対策. 臨床精神薬理 9 : 2011-2016, 2006.
 
5) 和田清ほか : 薬物使用に関する全国住民調査. 平成17年度厚生労働科学研究補助金 (医薬品・医療機器等レギュラトリーサイエンス総合研究事業) 「薬物乱用・依存の実態把握と乱用・依存者に対する対応策に関する研究」報告書, p17-106, 2006.
 
6) 井澤志名野, 村崎光邦 : ベンゾジアゼピン臨床用量依存と退薬症候の治療. 臨床精神薬理 6 : 1161-1168, 2003.
 
7) 鈴木勉 : A-2. 行動薬理的側面. 臨床精神医学講座8「薬物・アルコール関連障害」, p74-84, 中山書店, 1999.
 
8) Ridenour TA, et al : Factors associated with the transition from abuse to dependence among substance abusers : implications for a measure of addictive liability. Drug Alcohol Depend 80 (1) : 1-14, 2005.
PubMed
9) 尾崎茂ほか : 全国の精神科医療施設における薬物関連精神疾患の実態調査. 平成18年度厚生労働科学研究補助金 (医薬品・医療機器等レギュラトリーサイエンス総合研究事業) 「薬物乱用・依存の実態把握と乱用・依存者に対する対応策に関する研究」報告書, p93-140, 2007.
 
10) Kales A, et al : Lorazepam : effects on sleep and withdrawal phenomena. Pharmacology 32 : 121-130, 1986.
PubMed
11) WHO : ICD-10精神および行動の障害 (融道男ほか監訳), 医学書院, 1995.
 
12) Hallstrom C, Lader M : Benzodiazepine withdrawal phenomena. Int Pharmacopsychiatry 16 : 235-244, 1981.
PubMed
13) Busto U, et al : Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 315 : 854-859, 1986.
PubMed
P.365 掲載の参考文献
1) Alagiakrishnan K, Wiens CA : An approach to drug induced delirium in the elderly. Postgrad Med J 80 : 388 -393, 2004.
 
2) Trzepacz PT : The neuropathogenesis of delirium. A need to focus our research. Psychosomatics 35 : 374-391, 1994.
PubMed
3) Skoog I, et al : A population study on blood-brain barrier function in 85-year-olds : relation to Alzheimer's disease and vascular dementia. Neurology 50 : 966-971, 1998.
 
4) Chan D, Brennan NJ : Delirium : making the diagnosis, improving the prognosis. Geriatrics 54 : 28-30, 36, 39-42, 1999.
 
5) Inouye SK, Charpentier PA : Preciphating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. JAMA 275 : 852-857, 1996.
PubMed
6) Peet M : Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry 164 : 549-550, 1994.
PubMed
7) Breggin PR : Suicidality, violence and mania caused by selective serotonin uptake inhibitors (SSRIs) : A review and analysis. Int J Risk & Safety in Med 16 : 31-49, 2003/2004.
 
8) 野崎昭子, 稲田俊也 : 抗うつ薬の副作用とその対策. うつ病診療ハンドブック (樋口輝彦編), p 178-196, メディカルレビュー社, 2002.
 
9) Healy D, Whitaker C : Antidepressants and suicide : risk-benefit conundrums. J Psychiatry Neurosci 28 : 331-337, 2003.
PubMed
10) Khan A, et al : Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo : analysis of FDA reports. Am J Psychiatry 160 : 790-792, 2003.
PubMed
11) Tiihonen J, et al : Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 63 : 1358-1367, 2006.
 
12) Hammad TA, et al : Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63 : 332-339, 2006.
PubMed
13) Teicher MH, et al : Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147 : 207-210, 1990.
PubMed
14) Paton C : Benzodiazepines and disinhibition : a review. Psychiatric Bull 26 : 460-462, 2002.
 
15) Mancuso CE, et al : Paradoxical reactions to benzodiazepines : literature review and treatment options. Pharmacotherapy 24 : 1177-1185, 2004.
PubMed
P.371 掲載の参考文献
1) 千田要一, 久保千春 : 「うつ」と身体疾患. 臨床精神医学 35 (7) : 927-933, 2006.
Medical*Online
2) Patten SB, Love EJ : Drug-induced depression. Incidence, avoidance and management. Drug Saf 10 (3) : 203-219, 1994.
PubMed
3) 倉田健一, 山脇成人 : 「薬物によるうつ病」の診断・治療法. 医学と薬学 49 (6) : 847-849, 2003.
Medical*Online
4) 和田健 : 薬剤起因性うつ状態. 臨床と薬物治療 22 (2) : 107-109, 2003.
 
5) 加賀谷有里行, 山脇成人 (分担) : 薬物によるうつ病. 臨床精神医学講座4気分障害, p517-526, 中山書店, 1998.
 
6) American Psychiatric Association : Diagnostic and Statistical Manual of Mental Disorders, 4th ed, text revision DSM-IV-TR精神疾患の診断・統計マニュアル, p 390-394, 医学書院2002.
 
7) Patten SB, Barbui C : Drug-induced depression : a systematic review to inform clinical practice. Psychother Psychosom 73 (4) : 207-215, 2004.
PubMed
8) Kotlyar M, et al : Update on drug-induced depression in the elderly. Am J Geriatr Pharmacother 3 (4) : 288-300, 2005.
PubMed
9) 渡辺清美, 岡本泰昌 : うつ病の診断と鑑別診断. 精神科 6 (6) : 539-544, 2005.
 
10) Ried LD, et al : Beta-blockers and depression : the more the murkier? Ann Pharmacother 32 (6) : 699-708, 1998.
PubMed
11) 寺尾岳ほか : 医薬原性精神障害. 臨床精神医学講座17リエゾン精神医学・精神科救急医療, p112-121, 中山書店, 1998.
 
12) 松崎淳人 (分担) : インターフェロンとうつ症状. この薬のこの副作用, 第2版 (松田重三編), p44-47, 医歯薬出版, 2000.
 
13) 福井直樹, 染矢俊幸 : 精神疾患のファルマコジェネティクス. 綜合臨牀 54 (12) : 3023-3028, 2005.
Medical*Online
14) 山口潔, 大内尉義 : 老年科と「うつ」臨床精神医学 35 (7) : 979-988, 2006.
 
15) 阿部和彦 : 薬と精神症状, P79-82, 新興医学出版社, 1991.
 
P.376 掲載の参考文献
1) 厚生労働省 : 重篤副作用疾患別対応マニュアル. 神経・筋骨格系-白質脳症 (www.mhlw.go.jp/topics/2006/11/tp1122-1c.html).
 
2) 大越教夫ほか : 抗癌剤carmofurにより中枢神経障害を呈した1例. 内科 58 : 861-866, 1986.
 
3) 田村英二ほか : Carmofur脳症. 現代医療 21 : 1762-1767, 1989.
 
4) 安江正治ほか : 5FU誘導体に起因するとおもわれるToxic leucoencephalopathyの1例. 脳神経外科 13 : 1229-1234, 1985.
 
5) Kuzuhara S, et al : Subacute leucoencephalopathy induced by carmofur, a 5-fluorouracil derivative. J Neurol 234 : 365-370, 1987.
PubMed
6) 葛原茂樹 : 代謝性疾患-カルモフール白質脳症. Annual Review神経 (後藤文雄ほか編), p 263-275, 中外医学社, 1988.
 
7) 田村英二ほか : 投与中止により軽快したcarmofur脳症の2例. 神経内科治療 7 : 47-51, 1990.
Medical*Online
8) 三井製薬工業株式会社 : 医薬品再評価資料. 平成7年9月 (非公表).
 
9) Okeda R, et al : Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs. Acta Neuropathol 63 : 334-343, 1984.
 
10) 長沼睦雄ほか : 抗癌剤tegafurを服用中に自律神経障害および白質脳症を呈した1例. 臨床神経 28 : 1058-1064, 1988.
 
11) 笹崎義博ほか : 大量メソトレキセート静注による亜急性脳症の臨床的検討. 癌と化学療法 19 : 1851-1857, 1992.
Medical*Online
12) Sarazin M, et al : Primary central nervous system lymphoma : treatment with chemotherapy and radiotherapy. Eur J Cancer 31A : 2003-2007, 1995.
PubMed
13) Yokoo H, et al : Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis : an autopsy report. Acta Neuropathol 2007. (Epub)
 
14) Hinchey J, et al : A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334 : 494-500, 1996.
 
15) Mohad D, et al : Aciclovir induced posterior leucoencephalopathy. J Neurol Neurosurg Psychiatry 76 : 1308-1309, 2005.
 
P.380 掲載の参考文献
1) 厚生労働省 : 重篤副作用疾患別対応マニュアル 薬剤性パーキンソニズム, 平成18年11月. www.mhlw.go.jp/topics/2006/11/dl/tp1122-1c01.pdf
 
2) Kuzuhara S : Drug-induced parkinsonism. Nippon Rinsho 55 (1) : 112-117, 1997.
PubMed
3) Weinberger DR : Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44 (7) : 660-669, 1987.
PubMed
4) Fernandez HH, et al : Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 18 (5) : 510-514, 2003.
PubMed
5) Burris KD, et al : Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302 (1) : 381-389, 2002.
PubMed
6) Kuzuhara S : Iatrogenic neurological disorders in old people : a review. Nippon Ronen Igakkai Zasshi 42 (1) : 21-24, 2005.
PubMed
7) Teive HA, et al : Flunarizine and cinnarizine-induced parkinsonism : ahistorical and clinical analysis. Parkinsonism Relat Disord 10 (4) : 243-245, 2004.
 
8) Gerber PE, Lynd LD : Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 32 (6) : 692-698, 1998.
PubMed
9) Kwak YT, et al : Relation between cholinesterase inhibitor and Pisa syndrome, Lancet 355 (9222) : 2222, 2000.
PubMed
10) Sugiyama Y : [Parkinsonism induced by propiverine hydrochloride-report of 3 cases]. Rinsho Shinkeigaku 37 (10) : 873-875, 1997.
PubMed
11) Nagatomo S, et al : Manganese intoxication during total parenteral nutrition : report of two cases and review of the literature. J Neurol Sci 162 (1) : 102-105, 1999.
PubMed
12) Raison CL, et al : Neuropsychiatric adverse effects of interferon-alpha : recognition and management. CNS Drugs 19 (2) : 105-123, 2005.
 
13) Ondo WG, et al : Vascular parkinsonism : clinical correlates predicting motor improvement after lumbar puncture. Mov Disord 17 (1) : 91-97, 2002.
PubMed
P.385 掲載の参考文献
1) Jolles S, et al : Drug-induced aseptic meningitis : diagnosis and management. Drug Saf 22 : 215-226, 2000.
PubMed
2) Moris G, Garcia-Monco JC : The challenge of drug-induced aseptic meningitis. Arch Intern Med 159 : 1185-1194, 1999.
PubMed
3) Chez M, et al : Ibuprofen-induced meningitis : detection of intrathecal IgG synthesis and immune complexes. Neurology 39 : 1578-1580, 1989.
PubMed
4) Rodriguez SC, et al : Characteristics of meningitis caused by ibuprofen : report of 2 cases with recurrent episodes and review of the literature. Medicine 85 : 214-220, 2006.
PubMed
5) 木村淳 : CIDP, MMNに対する献血グロベニン-1-ニチヤクの使用成績調査結果 中間報告. 診療と新薬 40 : 297-316, 2003.
 
6) 白井丈晶ほか : 薬剤による無菌性髄膜炎. 小児科 44 : 1536-1540, 2003.
 
7) Joffe AM, et al : Trimethoprim-sulfamethoxazole-associated aseptic meningitis : case reports and review of the literature. Am J Med 87 : 332-338, 1989.
PubMed
8) Periard D, et al : Recurrent ibuprofen-induced aseptic meningitis : evidence against an antigen-specific immune response. Neurology 67 : 539-540, 2006.
PubMed
9) 木ノ本景子, 高山吉弘 : 鎮痛剤を乱用している頭痛の患者では薬剤性髄膜炎を疑う. JIM : Journal of Integrated Medicine 11 : 1060-1061, 2001.
 
10) Lee RZ, et al : Ibuprofen-induced aseptic meningoencephalitis. Rheumatology 41 : 353-355, 2002.
PubMed
11) Ashton D, et al : Cognitive decline with chronic meningitis secondary to a COX-2 inhibitor. Age Ageing 33 : 408-409, 2004.
PubMed
12) 小川朋子ほか : Zopiclone (Amoban) によるdrug-induced meningo-encephalitisの1例. 臨床神経 39 : 868, 1999.
 
P.389 掲載の参考文献
1) D'Amico DJ, et al : Amiodarone keratopathy : drug-induced lipid storage disease. Arch Ophthalmol 99 : 257-261, 1981.
PubMed
2) Hayasaka S, et al : Interferon associated retinopathy. Br J Ophthalmol 82 : 323-325, 1998.
PubMed
3) 中村徹ほか : C型慢性肝炎に対するインターフェロン・リバビリン併用療法による網膜症. 日眼会誌 109 : 748-752, 2005.
 
4) 宮田幹夫ほか : 視神経に対する薬物障害. 眼科 34 : 1165-1170, 1992.
 
5) Siddall JR : The ocular toxic findings with prolonged and high dosage chlorpromazine intake. Arch Ophthalmol 74 : 460-464, 1965.
PubMed
6) 窪田靖夫 : 薬物による網膜変性. 眼科MOOK, No 26 (窪田靖夫編), p 212-217, 金原出版, 1985.
 
7) 佐々木洋 : 白内障の発症機序と臨床 ステロイド白内障. 眼科 45 : 1277-1289, 2003.
 
8) Clark AF, et al : Steroid-induced glaucoma. In : The Glaucomas, Chapter 18, p 197-206, Thieme Medical Publishers, New York, 2003.
 
9) 宋鄂ほか : 中心性漿液性網脈絡膜症とステロイド剤の関係の検討. 日眼会誌 101 : 257-264, 1997.
 
10) McGwin G Jr, et al : Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction. Br J Ophthalmol 90 : 154-157, 2006.
PubMed
11) 伊藤正, 田中敦子 : 経口抗がん剤S-1による角膜障害の3例. 日眼会誌 110 : 919-923, 2006.
 
12) Krauss GL, et al : Vigabatrin-associated retinal cone system dysfunction : electroretinogram and ophthalmologic findings. Neurology 50 : 614-618, 1998.
PubMed
13) 二木芳人ほか : 深在性真菌症に対するvoriconazoleの臨床試験-多施設共同, 非対照試験-. 日本化学療法学会雑誌 53 (S-2) : 32-48, 2005.
 
P.393 掲載の参考文献
1) 清水輝夫, 山田広樹 筋疾患の分類. 内科学, 第8版 (杉本恒明ほか編), p2152-2154, 朝倉書店, 2003.
 
2) Pasternak RC, et al : ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40 : 567-572, 2002.
PubMed
3) Guis S, et al : Drug-induced and toxic myopathies. Best Pract Res Clin Rheumatol 17 : 877-907, 2003.
PubMed
4) Graham DJ, et al : Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292 : 2585-2590, 2004.
PubMed
5) 二見高弘ほか : コレステロール合成系の中間代謝物産生抑制 (2). 医薬ジャーナル 42 : 1743-1751, 2006.
 
6) Antons KA, et al : Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 119 : 400-409, 2006.
PubMed
7) Owczarek J, et al : Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol Rep 57 : 23-34, 2005.
PubMed
8) 安藤仁, 藤村昭夫 : HMG-CoA還元酵素阻害薬の薬物相互作用. Prog Med 25 : 2637-2640, 2005.
Medical*Online
9) 藤村昭夫ほか : 高脂血症. 疾患別これでわかる薬物相互作用, 第3版 (藤村昭夫編), p46-64, 日本医事新報社, 2006.
 
10) 辰巳文則, 加来浩平 : 横紋筋融解症. 臨牀と研究 83 : 1177 -1182, 2006.
 
11) 熊本俊秀 : 横紋筋融解症. 別冊日本臨牀 骨格筋症候群 (下), p235-238, 日本臨牀社, 2001.
 
12) Ando H, et al : Etifects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 60 : 494-497, 2005.
PubMed
13) Naba H, et al : Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats. Biochem Biophys Res Commun 340 : 215-220, 2006.
PubMed
P.398 掲載の参考文献
1) Seeman E, Delmas PD : Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 354 : 2250-2261, 2006.
PubMed
2) de Bosscher K, et al : The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1 : molecular mechanisms for gene repression. Endocr Rev 24 : 488-522, 2003.
 
3) Cohen D, Adachi JD : The treatment of glucocorticoid-induced osteoporosis. J Steroid Biochem Mol Biol 88 : 337-349, 2004.
 
4) Canalis E : Mechanisms of glucocorticoid-induced osteoporosis. Curr Opin Rheumatol 15 : 454-457, 2003.
PubMed
5) Okada Y, Tanaka Y : Immune signals in the context of secondary osteoporosis. Histol Histopathol 19 : 863-866, 2004.
 
6) Lobo RA : Potential options for preservation of fertility in women. N Engl J Med 353 : 64-73, 2005.
PubMed
7) Schulte CM, Beelen DW : Bone loss following hematopoietic stem cell transplantation : a long-term follow-up. Blood 103 : 3635-3643, 2004.
PubMed
8) van Staa TP, et al : The epidemiology of corticosteroid-induced osteoporosis : ameta-analysis. Osteoporos Int 13 : 777-787, 2002.
 
9) Amin S, et al : The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis : a meta-regression. J Bone Miner Res 17 : 1512-1526, 2002.
PubMed
10) Adachi JD, et al : Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids : a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44 : 202-211, 2001.
 
11) de Nijs RN, et al ; STOP Investigators : Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 355 : 675-684, 2006.
PubMed
12) Nakayamada S, et al : Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases. J Rheumatol 31 : 163-166, 2004.
PubMed
13) Nawata H, et al ; The Subcommittee to Study Diagnostic Criteria for Glucocorticoid-lnduced Osteoporosis : Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 23 : 105-109, 2005.
 
14) Soen S, Tanaka Y : Glucocorticoid-induced osteoporosis : skeletal manifestations of glucocorticoid use and 2004 Japanese Society for Bone and Mineral Research-proposed guidelines for its management. Mod Rheumatol 15 : 163-168, 2005.
PubMed
15) McClung MR, et al ; AMG 162 Bone Loss Study Group : Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 : 821-831, 2006.
 
P.404 掲載の参考文献
1) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会 (編) : 特発性間質性肺炎 診断と治療の手引き, 南江堂, 2004.
 
2) 近藤有好 : 間質性肺炎. 最新医学 45 : 962-972, 1990.
Medical*Online
3) 医薬品副作用情報 (厚生省薬務局) : インターフェロン-α製剤及び小柴胡湯と間質性肺炎. 日本医師会雑誌 109 : 278-281, 1993.
 
4) 築山邦規ほか : 小柴胡湯による薬剤誘起性肺炎の1例. 日胸疾会誌 27 : 1556-1561, 1989.
 
5) 日本呼吸器学会薬剤性肺障害ガイドライン作成委員会 (編) : 薬剤性肺障害の評価, 治療についてのガイドライン, p19-20, メディカルレビュー社, 2006.
 
6) Cooper JAD Jr, et al : Drug-induced pulmonary disease. Part 1 : Cytotoxic drugs. Am Rev Respir Dis 133 : 321-340, 1986.
 
7) Cooper JAD Jr, et al : Drug-induced pulmonary disease. Part 2 : Noncytotoxic drugs. Am Rev Respir Dis 133 : 488-505, 1986.
 
8) Ueda T, et al : Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 146 : 266-268, 1992.
PubMed
9) 大田健ほか : 特発性間質性肺炎の病因をめぐって-2. ウイルス説の立場から (1) HCVに関する検討結果-. 日胸疾会誌 31 (増) : 32-35, 1993.
 
P.409 掲載の参考文献
1) Reeder WH, Goodrich BE : Pulmonary infiltration with eosinophilia (PIE syndrome). Ann Intern Med 36 : 1217-1240, 1952.
PubMed
2) Allen JN, et al : Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med 321 : 569-574, 1989.
PubMed
3) 佐々木隆ほか : 喫煙による急性好酸球性肺炎の1例. 日胸疾会誌 35 (1) : 89-94, 1997.
 
P.413 掲載の参考文献
1) 磯谷澄都, 榊原博樹 : アスピリン喘息. 臨牀と研究 80 : 2026-2031, 2003.
Medical*Online
2) 榊原博樹, 末次勸 : 気管支喘息の分類はいかにあるべきか 病因・病態, 治療との関連において非アレルギー 気管支喘息の病型分類とアスピリン喘息. 日胸疾会誌 33 : 106-115, 1995.
 
3) Szczeklik A, et al : Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol 60 (5) : 276-284, 1977.
PubMed
4) Szczeklik A : The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 3 (5) : 588-593, 1990.
PubMed
5) Szczeklik A, Sanak M : The role of COX-1 and COX-2 in asthma pathogenesis and its significance in the use of selective inhibitors. Clin Exp Allergy 32 : 339-342, 2002.
PubMed
6) 谷口正実ほか : アスピリン喘息の新展開. 最新医学 58 (2) : 257-263, 2003.
Medical*Online
7) Kowalski ML, et al : Differential effects of aspirin and misoprostol on 15-hydroxyeicosatetraenoic acid generation by leukocytes from aspirin-sensitive asthmatic patients. J Allergy Clin Immunol 112 (3) : 505-512, 2003.
PubMed
8) Sanak M, et al : Aspirin-tolerant asthmatics generate more lipOxins than aspim -intolerant asthmatics. Eur Respir J 16 (1) : 44-49, 2000.
 
9) Antczak A, et al : Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 166 (3) : 301-306, 2002.
PubMed
10) 榊原博樹 : 内科からみたアスピリン喘息. アレルギーの臨床 24 (5) : 349-354, 2004.
 
11) 谷口正実ほか : アスピリン喘息の誘発試験の方法. アレルギーの臨床 22 : 566-569, 2002.
 
12) 谷口正実 : 特集・非ステロイド抗炎症薬 (NSAID) の使い方-NSAIDの副作用 気管支喘息とNSAID-. クリニカ 31 : 74-78, 2004.
 
13) Berges-Gimeno MP, et al : Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 111 (1) : 180-186, 2003.
PubMed
14) 比野平恭之 : アスピリン喘息と鼻副鼻腔手術. JOHNS 19 (6) : 869-874, 2003.
 
P.419 掲載の参考文献
1) 黒川顕 (編) : 中毒症のすべて, 永井書店, 2006.
 
2) 武田文和 : がんの痛みの鎮痛薬治療マニュアル, 改訂第2版, 金原出版, 2005.
 
3) 峯徹哉ほか : Sedationガイドライン. 消化器ガイドライン, 第3版 (日本消化器内視鏡学会卒後教育委員会編), 医学書院, 2006.
 
4) Charney DS, et al : 催眠薬及び鎮静薬. グッドマン・ギルマン薬理書, 第10版 (高折修二ほか監訳), p499-518, 廣川書店, 2003.
 
5) Howard B, et al : オピオイド鎮痛剤. グッドマン・ギルマン薬理書, 第10版 (高折修二ほか監訳), p718-786, 廣川書店, 2003.
 
P.425 掲載の参考文献
1) Fuck MR, Matthay MA : Pulmonary edema and acute lung injury. In : Textbook of Respiratory Medicine, 3rd ed (ed by Murray JF, Nadel JA), p 1575-1629, Elsevier Saunders, Philadelphia, 2000.
 
2) 久保惠嗣 : 肺循環障害. 内科学, 第8版 (杉本恒明ほか編), p859-869, 朝倉書店, 2003.
 
3) Lee-Chiong T Jr, Matthay RA : Drug-induced pulmonary edema and acute respiratory distress syndrome. Clin Chest Med 25 : 95-104, 2004.
PubMed
4) 日本呼吸器学会ARDSガイドライン作成委員会 (編) : ALI/ARDS診療のためのガイドライン, 秀潤社, 2005.
 
5) Chihara R, et al : Systemic capillary leak syndrome. Intern Med 41 : 953-956, 2002.
PubMed
6) Mackie FE, et al : Pulmonary capillary leak syndrome with intravenous cyclosporin A in pediatric renal transplantation. Pediatr Transplant 4 : 35-38, 2000.
PubMed
7) Biswas S, et al : Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in apatient with advanced pancreatic cancer and high-risk cardiovascular disease. Clin Oncol (R Coll Radiol) 16 : 577-579, 2004.
 
8) Quan W Jr, et al : Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over. Cancer Biother Radiopharm 20 : 11-15, 2005.
 
9) Deeren DH, et al : Granulocyte colony-stimulating factor-induced capillary leak syndrome confirmed by extravascular lung water measurements. Ann Hematol 84 : 89-94, 2005.
PubMed
10) Kopko PM, Popovsky MA : Pulmonary injury from transfusion-related acute lung injury. Clin Chest Med 25 : 105-111, 2004.
PubMed
11) 厚生労働省 : 重篤副作用疾患別対応マニュアル (http://www.info.pmda.go.jp/juutoku/).
 
12) 日本呼吸器学会薬剤性肺障害ガイドライン作成委員会 (編) : 薬剤性肺障害の評価. 治療についてのガイドライン, 日本呼吸器学会, 2006.
 
13) Fraser RS, et al (ed) : Pulmonary disease caused by drugs, poisons, and irradiation. In : Synopsis of Diseases of the Chest, 3rd ed, p 764-981, Elsevier Saunders, Philadelphia, 2005.
 
14) PNEUMOTOX ON LINE (http://www.pneumotox.com).
 
15) 医薬品医療機器情報ホームページ (http://www.info.pmda.go.jp).
 
16) 工藤翔二 : 日本人にとっての薬剤性肺障害. 日本胸部臨床 65 : 963-970, 2006.
Medical*Online
P.429 掲載の参考文献
1) Antzelevitch A : Drug-induced channelopathies. In : Cardiac Electrophysiology : From Cell to Bedside (ed by Zipes DP, Jalife J), p 151-157, Saunders, Philadelphia, 2004.
 
2) Ray WA, et al : Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351 : 1089-1096, 2004.
PubMed
3) Straus SM, et al : Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 26 : 2007-2012, 2005.
PubMed
4) ICH Harmonised Tripartite Guideline, The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Released for consultation at step 4 of the ICH process, The ICH Steering Committee, 2005.
 
5) 草野研吾ほか : 後天性QT延長症候群の臨床的研究. 臨床薬理 37 : 227-230, 2006.
 
6) 岸田浩 : 循環器系副作用症例及び文献情報からの評価法等の検討に関する研究. 厚生労働省科学研究費補助金 (医薬品等医療技術リスク評価研究事業). 平成14年度, 15年度分担研究報告書, p25-28, 2003, p16-21, 2004.
 
7) 山田雅信 : 安全対策に関わる行政の立場から. 医歯ジャーナル 41 : 2764, 2005.
 
8) 岸田浩 : 循環器系副作用症例及び文献情報からの評価法等の検討に関する研究. 厚生労働省科学研究費補助金 (医薬品等医療技術リスク評価研究事業). 平成16年度分担研究報告書, p12-15, 2005.
 
9) Justo D, et al : Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand 111 : 171-176, 2005.
PubMed
10) Yang P, et al : Allelic variants in long-QT disease genes in patients with drug-associated torsade de pointes. Circulation 105 : 1943-1948, 2002.
PubMed
11) Mitcheson JS, et al : A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97 : 12329-12333, 2000.
PubMed
12) 佐藤信範ほか : 薬剤相互作用におけるQT延長リスクの検討. 厚生労働省科学研究費補助金 (医薬品等医療技術リスク評価研究事業). 平成14年度, 15年度分担研究報告書, p6-18, 2003, p7-15, 2004.
 
13) Aiba T, et al : Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol 45 : 300-307, 2005.
PubMed
14) Kubo Y, et al : Postural change-associated alterations in QT/QTc intervals on electrocardiograms. J Arrhythmia 21 : 528-535, 2005.
 
15) 清水渉 : Torsade de Pointes. 抗不整脈薬の新たな展開 (新博次編), p 254-272, 医薬ジャーナル社, 2003.
 
P.435 掲載の参考文献
1) Benjamin EJ, et al : Impact of atrial fibrillation on the risk of death : the Framingham Heart Study. Circulation 98 (10) : 946-952, 1998.
PubMed
2) 西村敬史 : 心房細動-リズムコントロールとレートコントロール. 日内会誌 95 (2) : 100-106, 2006.
 
3) Corley SD, et al ; AFFIRM Investigators : Relationships between sinus rhythm, treatment, and sur vival in the Atrial Fibrillation Follow-Up lnvestigation of Rhythm Management (AFFIRM) Study. Circulation 109 (12) : 1509-1513, 2004.
 
4) Kennedy HL, et al : Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol 74 (7) : 674-680, 1994.
PubMed
P.439 掲載の参考文献
1) 竹端均ほか : 心筋炎. 目でみる循環器病シリーズ14心筋症 (松森昭編), p178-186, メジカルビュー社, 2000.
 
2) 和泉徹ほか : 急性および慢性心筋炎の診断・治療に関するガイドライン. Circ J 68 (Suppl IV) : 1231-1263, 2004.
 
3) Berry GJ, Atkins KA : Pathology of human myocarditis. In : MYOCARDITIS From Bench to Bedside (ed by Cooper LT), p 350-353, Humana Press, Totowa, 2003.
 
4) Billingham M : Pharmacotoxic myocardial disease. An endomyocardial study. In : Myocarditis and Related Disorders : Proceedings of the Intemational Symposium on Cardiomyopathy and Myocarditis (ed by Sekiguchi M, et al), p 278-282, Springer-Verlag, Tokyo, 1985.
 
5) Daniels PR, et al : Giant cell myocarditis as a manifestation of drug hypersensitivity. Cardiovasc Pathol 9 : 287-291, 2000.
PubMed
6) 竹越襄ほか : 急性重症心不全治療ガイドライン. Circ J 64 (Suppl IV) : 1129-1165, 2000.
 
P.443 掲載の参考文献
1) Olson RD, Mushlin PS : Doxorubicin cardiotoxicity : analysis of prevailing hypotheses. FASEB J 4 : 3076-3086, 1990.
PubMed
2) Legha SS, et al : Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96 : 133-139, 1982.
PubMed
3) Schwartz RG, et al : Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 82 : 1109-1118, 1987.
PubMed
4) Braverman AC, et al : Cyclophosphamide cardiotoxicity in bone marrow transplantation : a prospective evaluation of new dosing regimens. J Clin Oncol 9 : 1215-1223, 1991.
PubMed
5) Goldberg MA, et al : Cyclophosphamide cardiotoxicity : an analysis of dosing as a risk factor. Blood 68 : 1114-1118, 1986.
PubMed
6) Gottdiener JS, et al : Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 141 : 758-763, 1981.
PubMed
7) Rowinsky EK, Donehower RC : Paclitaxel (taxol). N Engl J Med 332 : 1004-1014, 1995.
PubMed
8) Gianni L, et al : Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer : high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13 : 2688-2699, 1995.
 
9) Suter TM, et al : Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 13 : 173-183, 2004.
PubMed
10) Von Hoff DD, et al : Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91 : 710-717, 1979.
PubMed
11) Seidman A, et al : Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20 : 1215-1221, 2002.
PubMed
12) Zbinden G : Effects of recombinant human alpha-interferon in a rodent cardiotoxicity model. Toxicol Lett 50 : 25-35, 1990.
 
13) Sonnenblick M, Rosin A : Cardiotoxicity of interferon. A review of 44 cases. Chest 99 : 557-561, 1991.
PubMed
14) Kobayashi T, et al : Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha-interferon. Intern Med 31 : 936-940, 1992.
PubMed
15) Sartori M, et al : Assessment of interferon cardiotoxicity with quantitative radionuclide angiocardiography. Eur J Clin Invest 25 : 68-70, 1995.
PubMed
P.448 掲載の参考文献
1) Feenstra J, et al : Drug-induced heart failure. J Am Coll Cardiol 33 : 1152-1162, 1999.
PubMed
2) 倉林正彦 : 癌領域の薬剤の心血管作用. 呼吸と循環 54 (5) : 485-491, 2006.
 
3) Mertens AC, et al : Late mortality experience in five-year survivors of childhood and adolescent cancer : the Childhood Cancer Survivor Study. J Clin Oncol 19 : 3163-3172, 2001.
 
4) Iwamoto R, et al : Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci USA 100 : 3221-3226, 2003.
PubMed
5) Crone SA, et al : ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8 : 459-465, 2002.
PubMed
6) Liu X, et al : Domain-specific gene disruption reveals critical regulation of neuregulin signaling by its cytoplasmic tail. Proc Natl Acad Sci USA 95 : 13024-13029, 1998.
PubMed
7) Dormandy JA, et al ; PROactive investigators : Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events) : a randomised controlled trial. Lancet 366 : 1279-1289, 2005.
PubMed
8) Lipshultz SE, et al : The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351 : 145-153, 2004.
PubMed
9) Speyer JL, et al : Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319 : 745-752, 1988.
PubMed
P.454 掲載の参考文献
1) Jordan WM : Pulmonary embolism. Lancet 2 : 1146-1147, 1961.
 
2) Rosendaal F : Risk factors for venous thrombotic disease. Thromb Haemost 82 : 610-619, 1999.
PubMed
3) Hulley S, et al : Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 280 : 605-613, 1998.
 
4) Writing Group for Women's Health Initiative Investigators : Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288 : 321-333, 2002.
 
5) Adachi T, Sakamoto S : Thromboembolism during hormone therapy in Japanese women. Semin Thromb Haemost 31 (3) : 272-280, 2005.
 
6) 小林隆夫 : HRTにおける予防と管理. 綜合臨牀 55 : 1906-1912, 2006.
Medical*Online
7) Kamijo Y, et al : Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines. Circ J 67 : 46-48, 2003.
PubMed
8) 日本総合病院精神医学会 教育・研究委員会 : 静脈血栓塞栓症予防指針, 星和書店, 2006.
 
9) Scholz M, et al : High association of anticardiol ipin antibodies With psychosis. J Clin Psychiatry 59 : 20-23, 1998.
 
10) Orr MW, et al : The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients. Br J Clin Pharmacol 11 : 255-259, 1981.
PubMed
11) 佐久間聖仁ほか : 急性肺塞栓症の診断と治療法の変化-肺塞栓症研究会共同作業部会報告-. Ther Res 23 : 602-603, 2002.
 
12) 肺血栓塞栓症および深部静脈血栓症の診断・治療・予防に関するガイドライン : 循環器病の診断と治療に関するガイドライン (2002-2003年度合同研究班報告). Jpn Circ J 68 : 1079-1152, 2004.
 
13) Yamada N, et al : Pulse-spray pharmacomechanical thrombolysis for proximal deep vein thrombosis. Eur J Vasc Endovasc Surg 31 : 204-211, 2006.
PubMed
14) Yamamoto S, et al : Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis 28 : 82-85, 1996.
PubMed
15) Matsuo T, et al : Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia. Thromb Res 115 : 475-481, 2005.
PubMed
P.459 掲載の参考文献
1) Young NS, Maciejewski Jp : Aplastic anemia. In : Hematology Basic Principles and Practice (ed by Hoffman R, et al), p 381-417, Elsevier Churchill Livingstone, Philadelphia, 2005.
 
2) 梅野美一 : 薬剤起因性再生不良性貧血. 別冊日本臨牀 血液症候群I, p18-21, 日本臨牀社, 1998.
 
3) 笹田昌孝 : 薬剤と血液疾患. 三輪血液病学 (浅野茂隆ほか編), p1855-1866, 文光堂, 2006.
 
4) Garnett HM, et al : Effect of in vivo exposure to benzene on the characteristics of bone marrow adherent cells. Leuk Res 7 : 803-810, 1983.
PubMed
5) Guinan EC, Shimaura A : Acquired and inherited aplastic anemia syndromes. In : Wintrobe's Clinical Hematology (ed by Greer JP, et al), p 1397-1419, Lippincott Williams and Wilkins, Philadelphia, 2004.
 
6) 平井久丸ほか : 造血器. 薬物障害ガイド 発症メカニズムと原因薬物 (藤田敏郎ほか編), p159-175, 南山堂, 1999.
 
7) 北見啓之, 山口毅一 : リンパ球を用いた薬剤アレルギーの診断. 臨床免疫 15 : 727-736, 1983.
 
8) Kelton JG, et al : The use of in vitro technics to study drug-induced pancytopenia. N Engl J Med 301 : 621-624, 1979.
PubMed
9) Carey PJ : Drug-induced myelosuppression : diagnosis and management. Drug Saf 26 : 691-706, 2003.
PubMed
10) 浦部晶夫, 壱岐聖子 : 再生不良性貧血. 別冊・医学のあゆみ 血液疾患State of arts Ver. 3 (坂田洋一, 小澤敬也編), p616-619, 医歯薬出版, 2005.
 
P.464 掲載の参考文献
1) 笹田昌孝 : 薬剤と血液疾患. 三輪血液病学, 第3版 (浅野茂隆ほか監), p1855-1866, 文光堂, 2006.
 
2) Watts RG : Neutropenia. In : Wintrobe's Clinical Hematology, 11th ed (ed by Lee GR, et al), p 1777-1800, Lippincott Williams & Wilkins, Baltimore, 2004.
 
3) Curnutte JT, Coats TD : Disorders of phagocyte number and function. In : Hematolgy ; Basic Principles and Practice, 3rd ed (ed by Hoffman R, et al), p 720-762, Churchill Livingstone, New York, 2000.
 
4) Dale DC, Liles WC : Neutrophils and monocytes : Normal physiology and disorders of neutrophil and monocyte production. In : Blood : Principles and Practice of Hematology, 2nd ed (ed by Handin R, et al), p 455-483, Lippincott Williams & Wilkins, Philadelphia, 2003.
 
5) 森下玲児ほか : 無穎粒球症患者についての全国アンケート調査の集計報告. 厚生省特定疾患特発性造血障害調査研究班昭和54年度研究業績報告書 (班長 : 内野治人), p39-48, 1980.
 
6) Dale DC : Neutropenia and neutrophilia. In : William's Hematology, 7th ed (ed by Lichtman MA, et al), p 907-919, McGraw-Hill, New York, 2006.
 
7) 厚生省薬務局 : 医薬品副作用モニター報告の概要. 医薬品副作用情報(15)-(17), 薬務広報社, 1993-1995.
 
8) 矢田純一 : リンパ球芽球化試験. 検査値のみかた (中井利昭編), p548-549, 中外医学社, 1996.
 
P.468 掲載の参考文献
1) Levine SP : Thrombocytopenia caused by immunologic platelet destruction. In : Wintrobe's Clinical Hematology, 11th ed (ed by Lee GR, et al), p 1533-1554, Lea & Febiger, Philadelphia, 2004.
 
2) George JN, et al : Drug-induced thrombocytopenia : asystematic review of published case reports. Ann Intern Med 129 : 886-890, 1998.
 
3) Rizvi MA, et al : Drug-induced thrombocytopenia : an updated systematic review. Ann Intern Med 134 : 346, 2001.
PubMed
4) Hibbard AB, et al : Reports of drug-induced thrombocytopenia. Ann Intern Med 138 : 239, 2003.
PubMed
5) Li X, et al : Drug-induced thrombocytopenia : an updated systematic review. Ann Intern Med 142 : 474-475, 2005.
PubMed
6) Li X, et al : Drug-induced thrombocytopenia : an updated systematic review, 2006. Drug Saf 30 : 185-186, 2007.
PubMed
7) Aster RH : Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 332 : 1374-1376, 1995.
PubMed
8) Warkentin TE : Drug-induced immune-mediated thrombocytopenia-from purpura to thrombosis. N Engl J Med 356 : 891-893, 2007.
PubMed
9) Pereira J, et al : Glycoprotein Ib/IX (complex is the target in rifampicin-induced immune thrombocytopenia. Br J Haematol 110 : 907-910, 2000.
PubMed
10) 桑名正隆 : 薬剤誘発性血小板減少症. 三輪血液病学 (浅野茂隆ほか編), p1645-1648, 文光堂, 2006.
 
11) Zondor SD, et al : Treatment of drug-induced thrombocytopenia. Expert Opin Drug Saf 1 : 173-180, 2002.
PubMed
12) Warkentin TE, et al : Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 : 1330-1335, 1995.
 
13) Arepally GM, Ortel TL : Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355 : 809-817, 2006.
PubMed
14) Warkentin TE : Management of heparin-induced thrombocytopenia : a critical comparison of lepirudin and argatroban. Thromb Res 110 : 73-82, 2003.
PubMed
15) Visentin GP, et al : Heparin is not required for detection of antibodies associated with heparininduced thrombocytopenia/thrombosis. J Lab Clin Med 138 : 22-31, 2001.
 
P.472 掲載の参考文献
1) 藤村欣吾 : 血栓性血小板減少性紫斑病. 今日の治療指針, p490-491, 医学書院, 2005.
 
2) Bennet CL, et al : Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 128 : 541-544, 1998.
 
3) 高橋隆一 : 血栓性血小板減少性紫斑病. 自覚症状から探る薬の副作用 (高橋隆一監), p160, 第一メディカル, 2004.
 
4) 松本雅則ほか : vWF-cleaving protease/ADAMTS13. 臨床血液 44 : 159-167, 2003.
 
5) 第一製薬資料 : 塩酸チクロピジンによる血栓性血小板減少性紫斑病症例69例の検討.
 
6) 厚生省医薬安全局 : 塩酸チクロピジンによる血栓性血小板減少性紫斑病 (TTP). 医薬品等安全性情報 156 : 2-5, 1999.
 
7) 鈴木美佐子, 村田満 : 血栓性血小板減少性紫斑病. 日本医師会雑誌 134 : 316-319, 2005.
 
8) Rock GA, et al : Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 325 : 393-397, 1991.
PubMed
P.477 掲載の参考文献
1) 池田和真 : 薬剤性貧血. 血液フロンティア 16 : 1607-1615, 2006.
 
2) 三浦亮 : 薬剤起因性溶血性貧血. 日本臨牀 54 : 2534-2538, 1996.
Medical*Online
3) 寺田秀夫 : 薬剤起因性溶血性貧血. 別冊日本臨牀 血液症候群I, p377-380, 日本臨牀社, 1998.
 
4) 金丸昭久 : 薬剤による溶血性貧血. 新臨床内科学, 第7版, p1011-1012, 医学書院, 1997.
 
5) 吉田彌太郎 : 薬剤による造血障害 近年の動向と対策. 血液フロンティア 16 : 1589-1595, 2006.
 
6) 寺田秀夫 : 溶血性貧血. 日本医事新報 No. 3607, 37-40, 1993.
 
7) 樋口敬和, 小峰光博 : 自己免疫性溶血性貧血とTTP/HUS. 高齢者の血液疾患 (森真由美編), p 213-225, 医薬ジャーナル社, 2005.
 
8) 斎藤英彦 : 血栓性血小板減少性紫斑病HUSも含めて. Modern Physician 23 : 251-255, 2003.
 
9) 寺田秀夫 : 成人にみられた溶血性尿毒症症候群の1例. 日常臨床に役立つ血液疾患治療症例集-私の経験例のなかから, p277-281, 医薬ジャーナル社, 2005.
 
10) 藤井寿一 : 赤血球酵素異常の検査. Medical Technology 32 : 573-578, 2004.
 
11) 狩野吉康ほか : C型慢性肝炎-新たな治療戦略2006-C型肝炎に対する抗ウイルス療法インターフェロン (ペグインターフェロン) ・リバビリン併用療法-副反応とその対策. カレントテラピー 24 : 697-700, 2006.
 
12) 坂本穣, 橋本信幸 : 主要な肝炎の特徴と治療選択 ウイルス性肝炎 C型肝炎. 消化器の臨床 9 : 255-260, 2006.
 
13) 達脇大ほか : 常用薬の副作用と注意するポイント 消化性潰瘍治療薬. 臨牀と研究 83 : 1127-1133, 2006.
Medical*Online
14) 寺田秀夫 : 臨床血液分野のトピックス (2) イマチニブによる免疫性溶血性貧血. 日本医事新報 No. 4] 89, 28, 2004.
 
15) Juliuson G : Complication in the treatment of CLL with purine analogues. Hematol Cell Ther 39 (Suppl 1) : 41-47, 1997.
 
16) Arndt PA, Garratty G : The changing spectrum of drug-induced hemolytic anemia. Semin Hematol 42 : 137-144, 2005.
PubMed
P.481 掲載の参考文献
1) 奈良信雄 : 再生不良性貧血. 疾患からまとめた病態生理FIRST AID (奈良信雄編), メディカルサイエンスインターナショナル社, 2007.
 
2) 奈良信雄 (訳) : ウィリアムズ血液学マニュアル, p31-35, メディカルサイエンスインターナショナル社, 2003.
 
3) Vandendries ER, Drews RE : Drug-associated disease : hematologic dysfunction. Crit Care Clin 22 : 347-355, 2006.
PubMed
4) Williams DM : Pancytopenia, aplastic anemia, and pure red cell aplasia. In : Wintrobe's Clinical Hematology (ed by Lee GR, et al), p 911-943, Lea & Febiger, Philadelphia, 1993.
 
5) Wallersrein RO, et al : Statewide study of chloramphenicol therapy and fatal aplastic anemia. JAMA 208 : 2045-2050, 1969.
 
6) Shadduck RK : Aplastic anemia. In : Williams Hematology (ed by Beutler E, et al), p238-251, McGraw-Hill, New York, 1995.
 
7) Young NS : Aplastic anemia, myelodysplasia, and related bone marrow failure syndromes. In : Harrison's Principle of Internal Medicine (ed by Kasper DL, et al), p617-626, McGraw-Hill, New York, 2005.
 
8) Nara N, et al : Effects of chloramphenicol on hematopoietic inductive microenvironment. Exp Hematol 10 (1) : 20-25, 1982.
PubMed
9) Young NS, Maciejewski J : The pathophysiology of acquired aplastic anemia. N Engl J Med 336 : 1365-1372, 1997.
PubMed
10) Young NS : Acquired aplastic ane. mia. Ann Intern Med 136 : 534-546, 2002.
 
11) Calado RT, et al : Reduced function of the multidrug resistance P-glycoprotein in CD34+ cell of patients with aplastic anaemia. Br J Haematol 118 : 320-326, 2002.
PubMed
12) Young NS, et al : Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 108 : 2509-2519, 2006.
PubMed
13) Ezzeldin H, et al : Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 9 : 3021-3028, 2003.
PubMed
P.486 掲載の参考文献
1) 金丸昭久 : 巨赤芽球性貧血. 新臨床内科学, 第8版 (高久史麿ほか監), p1183-1190, 医学書院, 2002.
 
2) Babior BM : Folate, cobalamin, and megaloblastic anemia. In : Williams Hematology, 7th ed (ed by Lichitman MA, et al), p 477-509, McGraw-Hill, New York, 2006.
 
3) Skacel PO, et al : Studies on the haemopoietic toxicity of nitrous oxide in man. Br J Haematol 53 : 189-200, 1983.
PubMed
4) Doran M, et al : Toxicity after intennittent inhaladon of nitrous oxide for analgesia. BMJ 328 : 1364-1365, 2004.
PubMed
5) Bradford GS, Taylor CT : Omeprazole and vitamin B12 deficiency. Ann Pharmacother 33 : 641-643, 1999.
PubMed
6) Ruscin JM, et al : Vitamin B (12) deficiency associated with histamine (2) -receptor antagonists and a proton-pump inhibitor. Ann Pharmacother 36 : 812-816, 2002.
 
7) Andres E, et al : Vitamin B (12) deficiency associated with chronic acid suppression therapy. Ann Pharmacother 37 : 1730, 2003.
PubMed
8) Callaghan TS, et al : Megaloblastic anaemia due to vitamin B12 malabsorption associated with long-term metformin treatment. Br Med J 280 : 1214-1215, 1980.
PubMed
9) Ting RZ, et al : Risk factors of vitamin Bl2 deficiency in patients receiving metformin. Arch Intern Med 166 : 1975-1979, 2006.
 
10) Vogelzang NJ, et al : Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 : 2636-2644, 2003.
PubMed
P.492 掲載の参考文献
1) Krotz F, et al : Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 42 : 312-324, 2005.
PubMed
2) Psaty BM, Weiss NS : NSAID trials and the choice of comparators-questions of public health importance. N Engl J Med 356 : 328-330, 2007.
PubMed
3) Hayashi T, et al : Plasma from patients with cirrhosis increases tissue plasminogen activator release from vascular endothelial cells in vitro. Liver 18 : 186-190, 1998.
PubMed
4) 内山真一郎 : ふたたび脚光を浴びる血栓溶解薬. 別冊医学のあゆみ 血液疾患-state of arts Ver. 3 (坂田洋一, 小澤敬也編), p605-609, 医歯薬出版, 2005.
 
5) Rettie AE, Tai G : The pharmocogenomics of warfarin : closing in on personalized medicine. Mol Interv 6 : 223-227, 2006.
 
6) Li T, et al : Identification of the gene for vitamin K epoxide reductase. Nature 427 : 541-544, 2004.
PubMed
7) Rost S, et al : Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 : 537-541, 2004.
PubMed
8) 医療用医薬品集2007, 日本医薬情報センター.
 
9) Chua JD, Friedenberg WR : Superwarfarin poisoning. Arch Intern Med 158 : 1929-1932, 1998.
PubMed
10) Pavlu J, et al : Superwarfarin poisoning. Lancet 365 : 628, 2005.
PubMed
P.496 掲載の参考文献
1) 小山高敏 : 播種性血管内凝固症候群 (DIC). 今日の治療指針2007, p 493-495, 医学書院, 2007.
 
2) Sallah S, et al : Comparative thrombotic event incidence after infusion of recombinant factor VIIa vs. factor VIII inhibitor bypass activity-a rebutta1. J Thromb Haemost 3 : 820-822 ; author reply 822, 2005.
PubMed
3) Aledort LM : Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2 : 1700-1708, 2004.
PubMed
4) Das KC, White CW : Activation of NF-κB by antineoplastic agents. Role of protein kinase C. J Biol Chem 272 : 14914-14920, 1997.
 
5) Butler J, et al : Systemic release of neutrophil elastase and tumour necrosis factor alpha following ABO incompatible blood transfusion. Br J Haematol 79 : 525-526, 1991.
PubMed
P.503 掲載の参考文献
1) Schiffman SS, et al : Effect of the nucleoside analogs zidovudine, didanosine, stavudine, and lamivudine on the sense of taste. Nutrition 15 (11-12) : 854-859, 1999.
 
2) Reynolds NR, et al : Patient appraisal of mandarin orange didanosine : implications for adherence and well-being. J Assoc Nurses AIDS Care 10 (1) : 35-41, 1999.
PubMed
3) Crooke ST, Mirabelli CK : Molecular mechanisms of action of auranofin and other gold complexes as related to their biologic actiVities. Am J Med 75 (6A) : 109-113, 1983.
PubMed
4) Markiewicz VR, et al : Carcinogenicity study of auranofin, an orally administered gold compound, in mice. Fundam Appl Toxicol 11 (2) : 277-284, 1988.
PubMed
5) Watanabe J, et al : Dose-dependent salivary excretion following bolus intravenous administration of lithium in dog. Chem Pharm Bull (Tokyo) 36 (8) : 3105-3112, 1988.
PubMed
6) Mizuno S, et al : Difference in saliva/plasma concentration ratio of endogenous urea between mandibular and parotid glands in dogs. Chem Pharm Bull (Tokyo) 36 (12) : 4921-4926, 1988.
PubMed
P.508 掲載の参考文献
1) Pirmohamed M, et al : Adverse drug reactions as cause of admission to hospital : prospective analysis of 18,820 patients. BMJ 329 (7456) : 15-19, 2004.
PubMed
2) 科学的根拠 (evidence) に基づく胃潰瘍診療ガイドラインの策定に関する研究班 : EBMに基づく胃潰瘍診療ガイドライン, p41-42, じほう, 2003.
 
3) Morris AJ, et al : Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. Lancet 337 (8740) : 520, 1991.
PubMed
P.511 掲載の参考文献
1) 日本医薬品集, じほう, 2005年7月版.
 
2) 青木照明 : 腸閉塞. 胃を切った人の後遺症 (石山俊二監, 梅田幸雄編), p15, 協和ブックス, 1984.
 
P.515 掲載の参考文献
1) 仲本雅子ほか : 潰瘍性大腸炎患者の合併症に関する検討. 京都府立医大誌 104 : 531-536, 1995.
 
2) 有田隆一ほか : ステロイドの吸収. 薬局 26 : 5-12, 1975.
 
3) 長澤浩平 : ステロイド性骨壊死症. 日内会誌 89 : 2122-2127, 2000.
 
4) 橋本博史 : 副腎皮質ステロイド薬. 日内会誌 88 : 1965-1970, 1999.
 
5) Motil KJ, et al : Growth failure in children with inflammatory bowel disease : a prospective study. Gastroenterology 105 : 681-691, 1993.
PubMed
6) Declerck D, et al : Pneumopathie interstitielle diffuse iatrogene liee au 5-aminosalicylate. Rev Mal Respir 11 : 292-293, 1994.
PubMed
7) 日比紀文ほか : 炎症性腸疾患の病態と治療. 日内会誌 93 : 499-504, 2004.
 
8) 松井敏幸 : 炎症性腸疾患に対する新しい内科治療. 日消誌 102 : 855-865, 2005.
Medical*Online
9) 骨粗鬆症の予防と治療ガイドライン作成委員会 (編) : 骨粗鬆症の予防と治療ガイドライン2006年版, ライフサイエンス出版, 2006.
 
P.519 掲載の参考文献
1) Coyne JD, et al : Involvement of the appendix in pseudomembranous colitis. J Clin Pathol 50 : 70-71, 1997.
PubMed
2) 久保徳彦ほか : Helicobacter Pylori除菌治療後に偽膜性腸炎を発症した1例. 感染症誌 80 : 51-55, 2006.
 
3) Finney JM : Gastro-enterostomy for cicatrix ulcer of the pylorus. Johns Hopkins Hosp Bull 4 : 53-55, 1893.
 
4) Buhling A, et al : Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. Aliment Pharmacol Ther 15 : 1445-1452, 2001.
PubMed
5) Hudson N, et al : Successful Helicobacter pylori eradication incorporating a one-week antibiotic regimen. Aliment Pharmacol Ther 9 : 47-50, 1995.
PubMed
6) 白井孝之ほか : 除菌療法中の副作用と対策. 臨床消化器内科 16 : 687-692, 2001.
 
7) Bartlett JG, et al : Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 298 : 531-534, 1978.
PubMed
8) Hall IC, et al : Intestinal flora in new-born infants. With a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child 49 : 390-402, 1935.
 
9) Bartlett JG : Antibiotic-associated diarrhea. Clin Infect Dis 15 : 573-581, 1992.
PubMed
10) 豊川真弘ほか : Clostridium difficile関連下痢症の迅速診断における糞便中のtoxin Aおよびtoxin B同時検出キットの有用性に関する検討. 感染症誌 81 : 33-38, 2007.
 
11) Fekety R : Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea nd colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 92 : 739-750, 1997.
 
12) Salcedo J, et al : Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41 : 366-370, 1997.
PubMed
13) Kelly CP, Lamont JT : Clostridium difficile infection. Annu Rev Med 49 : 375-390, 1998.
PubMed
14) 加藤はる, 加藤直樹 : Clostridium difficile 感染症と細菌学的検査. 臨床微生物誌 12 : 115-122, 2002.
 
15) McFarland LV, et al : Risk factors for Clostridium difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized patients. J Infect Dis 162 : 678-684, 1990.
 
16) Bliss DZ, et al : Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 129 : 1012-1019, 1998.
PubMed
P.524 掲載の参考文献
1) Runzi M, Layer P : Drug-associated pancreatitis : facts and fiction. Pancreas 13 : 100-109, 1996.
PubMed
2) Felly C, et al : The role of CFTR and SPINK-1 : mutations in pancreatic disorders in HIV-positive patients : a case-control study. AIDS 18 : 1521-1527, 2004.
 
3) Mallory A, Kern F : Drug-induced pancreatitis. Baillieres Clin Gastroenterol 2 : 293-307, 1988.
PubMed
4) Trivedi CD, Pitchmoni CS : Drug-induced pancreatitis. J Clin Gastroenterol 39 : 709-716, 2005.
 
5) Badalov N, et al : Drug-induced acute pancreatitis : an evidence based approach. Pancreas 33 : 444-445, 2006.
 
6) 大槻眞 : 厚生労働科学研究費補助金 難治性疾患克服研究事業 難治性膵疾患に関する調査研究 平成16年度総括・分担研究報告書, p56-63, 2004.
 
7) Lankisch PG, et al : Drug induced acute pancreatitis : incidence and severity. Gut 37 : 565-567, 1995.
PubMed
8) Adverse Drug Reactions Advisory Committee : Drug induced pancreatitis. Aust Adv Drug Reaction Bull 25 : 22, 2006.
 
9) 薬剤性膵炎. 医薬品安全性情報 4 (25) : 8-9, 2006.
 
10) Aboulafia D : Acute pancreatitis : a fatal complication of AIDS therapy. J Clin Gastroenterol 25 : 640-645, 1997.
PubMed
11) 急性膵炎の診療ガイドライン第2版作成出版委員会 (編) : 第V章 基本的診療方針と診療フローチャート. エビデンスに・基づいた急性膵炎の診療ガイドライン, 第2版, p50-72, 金原出版, 2007.
 
12) Foitzik T, et al : Effect of different immunosuppressive agents on acute pancreatitis : a comparative study in an improved animal model. Transplantation 65 (8) : 1030-1036, 1998.
 
13) 急性膵炎の診療ガイドライン第2版作成出版委員会 (編) : 第VII章 急性膵炎の重症度診断. エビデンスに基づいた急性膵炎の診療ガイドライン, 第2版, p74-90, 金原出版, 2007.
 
P.531 掲載の参考文献
1) 為田靱彦ほか : 薬剤性肝障害の全国集計. 最新肝臓学 (渡辺明治, 樋口清博編), p50-61, 新興医学, 2001.
 
2) 恩地森一 : 薬物性肝障害. 内科学, 第8版 (杉本恒明, 小俣政男編), p876-879, 朝倉出版, 2002.
 
3) Bissell DM, et al : Drug-induced liver injury : mechanisms and test systems. Hepatology 33 : 1009-1013, 2001.
PubMed
4) Watanabe I, et al : A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 73 : 435-455, 2003.
PubMed
5) Lebovitz HE : Differentiating members of the thiazolidinedione class : a focus on safety. Diabetes Metab Res Rev 18 : 23-29, 2002.
 
6) Huang YS, et al : Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis druginduced hepatitis. Hepatology 37 : 924-930, 2003.
PubMed
7) 舛本俊一, 恩地森一 : 薬物アレルギー性肝炎. 綜合臨牀 49 : 682-686, 2000.
Medical*Online
8) 馬越順子ほか : 薬物性肝炎の臨床病理学的検討-最近5年間の傾向について-. 肝臓 37 : 368-373, 1996.
 
9) 中野譲ほか : 桂枝湯のT cell subsets, mitogen活性におよぼす効果について. 和漢医薬学会誌 1 : 94-95, 1984.
 
10) Berg PA, Becker EW : The lymphocyte transformation test-a debated method for the evaluation of drug allergic hepatic injury. J Hepatol 22 : 115-118, 1995.
 
11) 滝川一ほか : DDW-J 2004ワークショップ薬物性肝障害診断基準の提案. 肝臓 46 : 85-90, 2005.
 
12) Murata H, et al : Detection and analysis of intracytoplasmic cytokines in peripheral blood mononuclear cells in patients with drug-induced liver injury. J Hepatol 38 : 573-582, 2003.
PubMed
13) 薬物性肝障害の診断基準案. 薬物と肝 (第3回薬物と肝研究会記録), p96-98, 杜陵印刷, 1978.
 
14) 恩地森一 : 薬物性肝炎の実態と対策. Medical Practice 19 : 997-1001, 2002.
Medical*Online
15) Danan G, Benichou C : Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings : application to drug-induced liver injuries. J Clin Epidemiol 46 : 1323-1330, 1993.
 
P.537 掲載の参考文献
1) 佐田通夫ほか : 痩せ薬・健康食品による薬物性肝障害二次全国調査集計結果. 肝臓 45 (2) : 96-108, 2004.
 
2) 三藤留美ほか : 薬物肝障害の実態と疫学. 医学のあゆみ 214 (10) : 765-769, 2005.
 
3) Andrade RI, et al : HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 39 : 1603-1612, 2004.
 
4) Kurosaki M, et al : HLA A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin. Dig Dis Sci 45 : 1103-1108, 2000.
PubMed
5) 滝川一ほか : DDW-J 2004ワークショップ 薬物性肝障害診断基準の提案. 肝臓 46 : 85-90, 2005.
 
6) Samuels AM, Carey MC : Effects of chlorpromazine hydrochloride and its metabolites on Mg2+ - and Na+, K+ -ATPase activities of canalicular-enriched rat liver plasma membranes. Gastroenterology 74 : 1183-1190, 1978.
PubMed
7) Kawahara H, et al : Effects of chlorpromazine and low calcium on the cytoskeleton and the secretory function of hepatocytes in vitro. J Hepatol 10 : 8-16, 1990.
PubMed
8) Klerman GL, Cole JO : Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol Rev 17 : 101-141, 1965.
PubMed
9) Weaver GA, et al : Hepatic sensitivity to imipramine. Am J Dig Dis 22 : 551-553, 1977.
PubMed
10) Larrey D, et al : Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut 33 : 368-371, 1992.
PubMed
11) Kowdley KV, et al : Prolonged cholestasis due to trimethoprim sulfamethoxazole. Gastroenterology 102 : 2148-2150, 1992.
PubMed
12) Rabinovitz M, Van Thiel DH : Hepatotoxicity of nonsteroidal anti-inflammatory drugs. Am J Gastroentrol 87 : 1696-1704, 1992.
 
13) Bossard R, et al : Ethinylestradiol treatment induces multiple canalicular membrane transport alterations in rat liver. J Clin Invest 91 : 2714-2720, 1993.
 
14) Kadmon M, et al : Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. Gastroenterology 104 : 1507-1514, 1993.
PubMed
15) Macarol V, et al : Hydrocortisone choleresis in the dog. J Clin Invest 49 : 1714-1723, 1970.
PubMed
P.544 掲載の参考文献
1) 滝川一 : 診断基準の変遷と概要. 医学のあゆみ 214 : 773-778, 2005.
Medical*Online
2) 為田靱彦ほか : 薬剤性肝障害の全国集計. 最新肝臓病学 (渡辺明治, 樋口清博編), p50-61, 新興医学出版社, 2001.
 
3) Chitturi S, Farrell GC : Drug-induced liver disease. In : Diseases of the Liver, 9th ed (ed by Schiff ER, et al), p 1059-1127, Lippincott Williams & Wilkins, Philadelphia, 2003.
 
4) Leeder JS, Parmohamed M : Anticonvulsant agents. In : Drug-induced Liver Disease (ed by Kaplowitz N, Deleve LD), p 425 -446, Marcel Dekker, New York, 2003.
 
5) De La Iglesia FA, et al : Hepatotoxicity of cardiovascular and antidiabetic drugs. In : Drug-induced Liver Disease (ed by Kaplowitz N, Deleve LD), p 549-592, Marcel Dekker, New York, 2003.
 
6) Carg PK, Tandon RK : Antituberculous agents-induced liver injury. In : Drug-induced Liver Disease (ed by Kaplowitz N, Deleve LD), p 505-517, Marcel Dekker, New York, 2003.
 
7) Lewis JH : Nonsteroidal anti-inflammatory drugs : pathology and clinical presentation of hepatotoxicity. In : Drug-induced Liver Disease (ed by Kaplowitz N, Deleve LD), p 377-404, Marcel Dekker, New York, 2003.
 
8) Farrell GC : Liver disease caused by drugs, anesthetics, and toxins. In : Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Management, 7th ed (ed by Feldman M, et al), p 1403-1447, Saunders, Philadelphia, 2002.
 
9) Westphal JF, Brogard JM : Antibacterials and antifungal agents. In : Drug-induced Liver Disease (ed by Kaplowitz N, Deleve LD), p 471-504, Marcel Dekker, New York, 2003.
 
10) Bonacini M, et al : Hepatic injury from antiviral agents. In : Drug-induced Liver Disease (ed by Kaplowitz N, Deleve LD), p 519-548, Marcel Dekker, New York, 2003.
 
11) Deleve L : Cancer chemotherapy. In : Drug-induced Liver Disease (ed by Kaplowitz N, Deleve LD), p593-632, Marcel Dekker, New York, 2003.
 
12) 神代龍吉 : 糖尿病治療薬と薬物性肝障害. 医学のあゆみ 214 : 799-803, 2005.
Medical*Online
13) Naeem M, Schenker S : Adverse effects of hormones and hormone antagonists on the liver. In : Drug-induced Liver Disease (ed by Kaplowitz N, Deleve LD), p 677 -708, Marcel Dekker, New York, 2003.
 
14) 清水幸裕, 田尻和人 : 免疫学的視点からみた診断の現状と今後の展望. 医学のあゆみ 214 : 791-795, 2005.
 
15) Lee W : Drug-induced hepatotoxicity. N Engl J Med 349 : 474-485, 2003.
PubMed
16) Scheuer PJ, Lefkowitch JH : Drug and toxins. In : Liver Biopsy Interpretation, 7th ed (ed by Scheuer PJ, Lefkowitch JH), p 125-144, Elsevier Saunders, Philadelphia, 2006.
 
P.548 掲載の参考文献
1) 犬山シンポジウム記録刊行会 (編) : 第12回犬山シンポジウム. A型肝炎・劇症肝炎, p110-230, 中外医学社, 1982.
 
2) 為田靭彦, 高瀬幸次郎 : 近年の本邦における薬物性肝障害. 肝胆膵 40 : 849-859, 2000.
 
3) Andrade RJ, et al ; Spanish Group for the Study of Drug-lnduced Liver Disease : Drug-induced liver injury : an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129 : 512-521, 2005.
 
4) Sherlock SA, Dooley J : Diseases of the Liver and Biliary System, 11th ed, Blackwell Science, 2002.
 
5) 佐田通夫ほか : 痩せ薬・健康食品による薬物性肝障害2次全国調査集計結果 (日本肝臓学会主催). 肝臓 45 : 96-108, 2004.
 
6) Lee WM : Drug-induced hepatotoxicity. N Engl J Med 349 : 474-485, 2003.
PubMed
7) 滝川一ほか : DDW-J 2004ワークショップ 薬物性肝障害診断基準の提案. 肝臓 46 : 85-90, 2005.
 
8) 安田宏, 与芝真彰 : 薬剤性肝障害の診断と治療. 日本薬剤師会雑誌 58 : 91-95, 2006.
 
9) 与芝真彰 : 劇症肝不全の内科的治療. 肝胆膵 51 : 95-100, 2005.
 
10) Yoshiba M, et al : Accurate prediction of fulminant hepatic failure in severe acute viral hepatitis : multicenter study. J Gastroenterol 37 : 916-921, 2002.
PubMed
P.553 掲載の参考文献
1) Biff FP, William LH : Analgesics and kidney. In : Primer on Kidney Diseases, 4th ed (ed by Greenberg AK), p 324, National Kidney Foundation, New York, 2005.
 
2) 志水英明ほか : CACASE 13薬剤性腎障害. New専門医を目指すケース・メソッド・アプローチ5腎臓疾患, (槇野博史編), p125-130, 日本医事新報社, 2007.
 
3) Palmer BF : Renal dysfunction complicating the treatment of hypertension. N Engl J Med 347 : 1256-1261, 2002.
PubMed
4) Biff FP, William LH : Toxic nephropathy. In : Brenner's & Rector's The Kidney, 7th ed (ed by Barry MB), p 1625, WB Saunders, Philadelphia, 2003.
 
5) Thomas MC : Kidney failure due to therapeutic agents. In : Primer on Kidney Diseases, 4th ed (ed by Greenberg AK), p 293, National Kidney Foundation, New York, 2005.
 
6) Levison ME : New dosing regimens for aminoglycoside antibiotics. Ann Intern Med 117 : 693-694, 1992.
PubMed
7) Karen LH : 腎障害時の薬物投与. WM腎臓内科コンサルト, p 317-323, メディカル・サイエンス・インターナショナル, 2006.
 
8) 宮里均 : 腎機能低下患者におけるガドリニウム系造影剤とNSFの関与の可能性について. 日本腎臓学会. http://www.jsn.or.jp/jsn』ew/iryou/kaiin/free/kaikoku/pages/NSF.htm
 
9) Dana M, et al : Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure. UpToDate, 2007.
 
P.558 掲載の参考文献
1) Nadasdy T, Sedmak D : Acute and chronic tubulointerstitial nephritis. In : Heptinstall's Pathology of the Kidney (ed by Jennette J-C, et al), p 1084-1137, Lippincott Williams & Wilkins, Philadelphia, 2007.
 
2) 安達政隆, 富田公夫 : 薬剤と腎. 初学者から専門医までの腎臓学入門 (日本腎臓学会編), p 152-161, 東京医学社, 2005.
 
3) 原田孝司 : 抗菌薬による薬物性腎障害-早期発見と予防. 医学のあゆみ 215 (6) : 523-527, 2005.
Medical*Online
4) 遠藤平仁, 近藤啓文 : 薬剤性腎障害 消炎鎮痛薬の腎障害. 腎と透析増刊号, p359-362, 2003.
 
5) 横山仁 : 薬物性腎障害診断のアプローチ. 医学のあゆみ 215 (6) : 511-515, 2005.
Medical*Online
6) 佐藤紀子, 上田志朗 : 間質性腎炎 アリストロキア酸腎症. 腎と透析 57 (6) : 765-772, 2004.
 
7) 両角久仁夫, 武田朝美 : 免疫抑制薬による薬物性腎障害. 医学のあゆみ 215 (6) : 533-539, 2005.
 
P.561 掲載の参考文献
1) 酒井紀 : 老人の薬剤性腎障害, 1996.
 
2) Liano F, Pascual J : Epidemiology of acute renal failure ; a prospective multicenter community based study. Kidney Int 50 : 811-818, 1996.
PubMed
3) Nash K, et al : Hospital-acquired renal insufficiency. Am J Kidney Dis 39 : 930-936, 2002.
PubMed
4) 榊間昌哲, 菱田明 : 急性腎不全の成因と予後. 腎と透析 61 : 13-17, 2006.
 
P.566 掲載の参考文献
1) Izzedine H, et al : Drug-induced glomerulopathies. Expert Opin Drug Saf 5 : 95-106, 2006.
PubMed
2) Hall CL, et al : The natural course of gold nephropathy : long term study of 21 patients. Br Med J 295 : 745-748, 1987.
 
3) Wooley PH, et al : HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med 303 : 300-302, 1980.
 
4) 中野正明ほか : 慢性関節リウマチにおける薬剤性腎障害. リウマチ 36 : 775-782, 1996.
 
5) Nagahama K, et al : Bucillamine induces membranous glomerulonephritis. Am J Kidney Dis 39 : 706-712, 2002.
PubMed
6) Whelton A : Nephrotoxicity of nonsteroidal anti-inflammatory drugs : physiologic foundations and clinical implications. Am J Med 106 : 13S-24S, 1999.
PubMed
7) Radford MG, et al : Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 276 : 466-469, 1996.
PubMed
8) Markowitz GS, et al : Lithium nephrotoxicity : a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 11 : 1439-1448, 2000.
PubMed
9) Izzedine H, et al : Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45 : 804-817, 2005.
PubMed
10) Ohta S, et al : Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy. Am J Kidney Dis 33 : 1040-1048, 1999.
PubMed
11) Coroneos E, et al : Focal segmental glomerulosclerosis with acute renal failure associated with α-interferon therapy. Am J Kidney Dis 28 : 888-892, 1996.
 
12) Green JR, et al : Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol ToXicol 80 : 225-230, 1997.
PubMed
13) Markowitz GS, et al : Focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12 : 1164-1172, 2001.
PubMed
P.571 掲載の参考文献
1) 厚生労働省, 重篤副作用疾患別対応マニュアル : 日本神経学会マニュアル作成委員会「横紋筋融解症」, 平成18年11月.
 
2) Niemi M, et al : High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14 : 429-440, 2004.
PubMed
3) Morimoto K, et al : SNP Communication. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab Pharmacokinet 19 : SNP33 (453) -SNP35 (455), 2004.
 
4) シクロスポリン. JAPIC医療用医薬品集2007 (日本医薬品情報センター編), p986-994, 日本医薬品情報センター, 2007.
 
5) Roberts MC, et al : Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1). Anesthesiology 95 : 716-725, 2001.
PubMed
6) Ebadi M, et al : Pathogenesis and treatment of neuroleptic malignant syndrome. Gen Pharmacol 21 : 367-386, 1990.
PubMed
7) Chubachi A, et al : Acute renal failure following hypokalemic rhabdomyolysis due to chronic glycyrrhizic acd administration. Intern Med 31 : 708-711, 1992.
 
P.574 掲載の参考文献
1) Thomas D, Dubose : Acid-base disorder. In : Brenner & Rector's The Kidney, 6th ed, p 925-934, WB Saunders, Philadelphia, 2000.
 
2) 飯田喜俊 : 酸塩基平衡の異常と治療. 日内会誌 80 (2) : 57-64, 1991.
 
3) 小出輝 : 薬物と電解質異常. 日内会誌 80 (2) : 46-56, 1991.
 
4) 黒川清 : 水・電解質と酸塩基平衡, 南江堂, 1996.
 
5) 鈴木洋通 : 乳酸アシドーシスの診断と治療. medicina 40 (11) : 1864-1866, 2003.
 
6) 吉田祥吾, 白水和雄 : TPN管理中の代謝性アシドーシス. 医学のあゆみ 183 (9) : 617-620, 1998.
 
7) 杉浦伸一, 谷村学 : 高カロリー輸液によるアシドーシス. 月刊薬事 40 (4) : 386-392, 1998.
 
P.581 掲載の参考文献
1) The Diabetes Control and Complications Trial Research Group : The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 : 977-986, 1993.
 
2) UK Prospective Diabetes Study (UKPDS) Group : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 : 837-853, 1998.
 
3) UK Prospective Diabetes Study (UKPDS) Group : Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 : 854-865, 1998.
PubMed
4) Stratton IM, et al : Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35) : prospective observational study. BMJ 321 : 405-412, 2000.
PubMed
5) Khaw KT, et al : Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ 322 : 15-18, 2001.
PubMed
6) Cryer PE : Hypoglycaemia : the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 45 : 937-948, 2002.
PubMed
7) Schwartz NS, et al : Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 79 : 777-781, 1987.
 
8) Mitrakou A, et al : Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 260 : E67-74, 1991.
PubMed
9) Fanelli C, et al : Relative roles of insulin and hypoglycaemia on induction of neuroendocrine responses to, symptoms of, and deterioration of cognitive function in hypoglycaemia in male and female humans. Diabetologia 37 : 797-807, 1994.
PubMed
10) Cryer PE, et al : Hypoglycemia in diabetes. Diabetes Care 26 : 1902-1912, 2003.
PubMed
11) Gerich JE, et al : Lack of glucagon response to hypoglycemia in diabetes : evidence for an intrinsic pancreatic alpha cell defect. Science 182 : 171-173, 1973.
PubMed
12) Bolli G, et al : Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion, Diabetes 32 : 134-141, 1983.
PubMed
13) Fukuda M, et al : Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes 37 : 81-88, 1988.
PubMed
14) Banarer S, et al : Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response. Diabetes 51 : 958-965, 2002.
PubMed
15) Amiel SA, et al : Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release. Diabetes 37 : 901-907, 1988.
 
16) Dagogo-Jack SE, et al : Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 91 : 819-828, 1993.
PubMed
17) Segel SA, et al : Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 51 : 724-733, 2002.
PubMed
18) Hepburn DA, et al : Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med 10 : 231-237, 1993.
PubMed
19) Boyle PJ, et al : Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics. N Engl J Med 318 : 1487-1492, 1988.
PubMed
20) Mitrakou A, et al : Reversibility of unawareness of hypoglycemia in patients with insulinomas. N Engl J Med 329 : 834-839, 1993.
PubMed
21) Boland E, et al : Limitations of conventional methods of self-monitoring of blood glucose : lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care 24 : 1858-1862, 2001.
PubMed
22) Reichard P, et al : Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM) : the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 230 : 101-108, 1991.
PubMed
23) MacLeod KM, et al : Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabet Med 10 : 238-245, 1993.
PubMed
24) Laing SP, et al : The British Diabetic Association Cohort Study, II : Cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med 16 : 466-471, 1999.
PubMed
25) Abraira C, et al : Veterans Nfairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Nfairs Cooperative Study in Type II Diabetes. Diabetes Care 18 : 1113-1123, 1995.
 
26) Saudek CD, et al ; Department of Veterans Affairs Implantable Insulin Pump Study Group : Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus : a randomized clinical trial. JAMA 276 : 1322-1327, 1996.
 
27) Towler DA, et al : Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes 42 : 1791-1798, 1993.
PubMed
28) McAulay V, et al : Symptoms of hypoglycaemia in people with diabetes. Diabet Med 18 : 690-705, 2001.
PubMed
29) Gold AE, et al : Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. Diabetes Care 17 : 697-703, 1994.
 
30) Grimaldi A, et al : Unawareness of hypoglycemia by insulin-dependent diabetics. Horm Metab Res 22 : 90-95, 1990.
PubMed
31) Clarke WL, et al : Multifactorial origin of hypoglycemic symptom unawareness in IDDM. Association with defective glucose counterregulation and better glycemic control. Diabetes 40 : 680-685, 1991.
PubMed
32) Hepburn DA, et al : Hypoglycaemia unawareness in type 1 diabetes : a lower plasma glucose is required to stimulate sympatho-adrenal activation. Diabet Med 8 : 934-945, 1991.
PubMed
33) Berlin I, et al : Hypoglycemic symptoms and decreased β-adrenergic sensitivity in insulin-dependent diabetic patients. Diabetes Care 10 : 742-747, 1987.
 
34) Korytkowski MT, et al : Reduced β-adrenergic sensitivity in patients with type 1 diabetes and hypoglycemia unawareness. Diabetes Care 21 : 1939-1943, 1998.
 
35) Fritsche A, et al : Effect of hypoglycemia on β-adrenergic sensitivity in normal and type 1 diabetic subjects. Diabetes Care 21 : 1505-1510, 1998.
 
36) Fritsche A, et al : Avoidance of hypoglycemia restores hypoglycemia awareness by increasing β-adrenergic sensitivity in type 1 diabetes. Ann Intern Med 134 : 729-736, 2001.
 
37) The Diabetes Control and Complications Trial Research Group : Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46 : 271-286, 1997.
 
38) Muhlhauser I, et al : Risk factors of severe hypoglycaemia in adult patients with Type I diabetes-a prospective population based study. Diabetologia 41 : 1274-1282, 1998.
PubMed
39) Wiethop BV, Cryer PE : Alanine and terbutaline in treatment of hypoglycemia in IDDM. Diabetes Care 16 : 1131-1136, 1993.
PubMed
40) Bolli GB : How to ameliorate the problem of hypoglycemia in intensive as well as nonintensive treatment of type 1 diabetes. Diabetes Care 22 (Suppl 2) : B43-52, 1999.
 
41) Heller SR, et al ; U. K. Lispro Study Group : Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensi6ed insulin therapy. Diabetes Care 22 : 1607-1611, 1999.
 
42) Brunelle BL, et al : Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 21 : 1726-1731, 1998.
PubMed
43) Home PD, et al ; UK Insulin Aspart Study Group : Improved glycemic control with insulin aspart : a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care 21 : 1904-1909, 1998.
 
44) Ratner RE, et al ; U. S. Study Group of Insulin Glargine in Type 1 Diabetes : Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 23 : 639-643, 2000.
 
45) Yki-Jarvinen H, et al ; HOE 901/3002 Study Group : Less nocturnal hypoglycemia and better postdinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23 : 1130-1136, 2000.
 
46) Hermansen K, et al : Comparison of the soluble basal insulin analog insulin detemir with NPH insulin : a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 24 : 296-301, 2001.
PubMed
47) U.K. Prospective Diabetes Study Group : U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes : a progressive disease. Diabetes 44 : 1249-1258, 1995.
 
48) Gerich JE : Oral hypoglycemic agents. N Engl J Med 321 : 1231-1245, 1989.
PubMed
49) Shorr RI, et al : Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 44 : 751-755, 1996.
 
50) Saloranta C, et al : Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 87 : 4171-4176, 2002.
PubMed
P.587 掲載の参考文献
1) Neil JL, et al : Drug-induced diabetes. In : Textbook of Diabetes 1 (ed by Pickup JC, Williams G), p26. 1-26. 12, Blackwell Science, Oxford, 2003.
 
2) Yoon JC, et al : Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413 : 131-138, 2001.
PubMed
3) Lambillotte C, et al : Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 99 : 414-423, 1997.
 
4) 飯野四郎 : アンケート調査集計 : インターフェロンの副作用. 厚生省難治性肝炎調査研究班, 平成5年度研究報告, p7, 1993.
 
5) Fabris P, et al : Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 18 : 549-558, 2003.
PubMed
6) Lean ME, Pajonk FG : Patients on atypical antipsychotic drugs : another high-risk group for type 2 diabetes. Diabetes Care 26 : 1597-1605, 2003.
 
7) Sasaki N, et al : The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets. Diabetologia 49 : 2930-2938, 2006.
PubMed
8) 笹岡利安 : 耐糖能異常. 綜合臨牀 52 : 2610-2615, 2003.
Medical*Online
9) Koller E, et al : Clozapine-associated diabetes. Am J Med 111 : 716-723, 2001.
PubMed
10) Andersson OK, et al : Metabolic adverse effects of thiazide diuretics : the importance of normokalemia. J Intern Med Suppl 735 : 89-96, 1991.
 
11) Charles S, et al : Hyperglycaemic effect of nifedipine. Br Med J 283 : 19-20, 1981.
 
12) Gress TW, et al : Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 342 : 905-912, 2000.
PubMed
13) Yoshioka K, et al : Post-transplant diabetes with anti-glutamic acid decarboxylase antibody during tacrolimus therapy. Diabetes Res Clin Pract 42 (2) : 85-89, 1998.
PubMed
14) Murata H, et al : The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 275 : 20251-20254, 2000.
PubMed
15) Park-Wyllie LY, et al : Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354 : 1352-1361, 2006.
PubMed
P.591 掲載の参考文献
1) Bartter FC, Schwartz WB : The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 42 : 790-806, 1967.
PubMed
2) 山本恭平ほか : 不適切ADH分泌症候群 (SIADH). 別冊日本臨牀 内分泌症候群 (上), p 142-145, 日本臨牀社, 1993.
 
3) 斎藤寿一 : SIADH (syndrome of inappropriate secretion of antidiuretic hormone). 日内会誌 74 : 691-695, 1985.
 
4) 石川三衛 : SIADHの診断基準. 内科 95 : 1786-1790, 2005.
 
5) Ishikawa S, et al : Close association of urinary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatremia in elderly subjects. J Clin Endocrinol Metab 86 : 1665-1671, 2001.
 
6) Adams RD, et al : Central pontine myelinolysis : a hitherto undescribed disease occurring in alcoholic and malnourished patients. AMA Arch Neurol Psychiatry 81 : 154-172, 1959.
PubMed
7) 吉田尚 : 内分泌異常に伴う電解質異常. 日内会誌 83 : 402-406, 1994.
 
P.595 掲載の参考文献
1) Fiore C, et al : A history of the therapeutic use of liquorice in Europe. J Ethnopharmacol 99 : 317-324, 2005.
 
2) Conn JW, et al : Licorice-induced pseudoaldosteronism. Hypertension, hypokalemia, aldosteronopenia, and suppressed plasma renin activity. JAMA 205 : 492-496, 1968.
PubMed
3) Sigurjonsdottir HA, et al : Subjects with essential hypertension are more sensitive to the inhibition of 11β-HSD by liquorice. J Hum Hypertens 17 : 125-131, 2003.
 
4) Tanahashi T, et al : Glycyrrhizic acid suppresses type 2 11β-hydroxysteroid dehydrogenase expression in vivo. J Steroid Biochem Mol Biol 80 : 441-447, 2002.
 
5) Quaschning T : Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 37 : 801-805, 2001.
PubMed
6) 河邊博史, 猿田享男 : アルドステロン症, 偽アルドステロン症. 循環科学 16 (3) : 224-227, 1996.
Medical*Online
7) 日本病院薬剤師会 (編) : 偽 (性) アルドステロン症. 重大な副作用回避のための服薬指導情報集, 第4集, p53-57, じほう, 2001.
 
8) Sambandam K, Vijayan A : Fluid and electrolytes management. Potassium. In : The Washington Manual of Medical Therapeutics (ed by Cooper DH, et al), 32nd ed, p 69-78, Lippincott Williams and Wilkins.
 
9) 森本靖彦, 中島智子 : 甘草製剤による偽アルドステロン症のわが国における現状. 和漢医薬学会誌 8 : 1-22, 1991.
 
10) 野畑俊介ほか : 漢方薬による偽アルドステロン症を契機に発見された内分泌非活性副腎腫瘍の1例. 泌尿紀要 47 : 633-635, 2001.
 
11) 入江正洋ほか : 神経症性うつ病に併発したグリチルリチン少量投与による偽アルドステロン症の1例. 内科 69 (4) : 795-799, 1992.
 

書評

最近チェックした商品履歴

Loading...